1
|
Go S, Tsuzuki Y, Yoneda H, Ichikawa Y, Ikeda T, Imai N, Imamura K, Niikura M, Nishimura D, Mizuno R, Takeda S, Ueno H, Watanabe S, Saito TY, Shimoura S, Sugawara S, Takamine A, Takahashi T. Demonstration of nuclear gamma-ray polarimetry based on a multi-layer CdTe Compton camera. Sci Rep 2024; 14:2573. [PMID: 38336981 DOI: 10.1038/s41598-024-52692-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2023] [Accepted: 01/22/2024] [Indexed: 02/12/2024] Open
Abstract
To detect and track structural changes in atomic nuclei, the systematic study of nuclear levels with firm spin-parity assignments is important. While linear polarization measurements have been applied to determine the electromagnetic character of gamma-ray transitions, the applicable range is strongly limited due to the low efficiency of the detection system. The multi-layer Cadmium-Telluride (CdTe) Compton camera can be a state-of-the-art gamma-ray polarimeter for nuclear spectroscopy with the high position sensitivity and the detection efficiency. We demonstrated the capability to operate this detector as a reliable gamma-ray polarimeter by using polarized 847-keV gamma rays produced by the [Formula: see text]([Formula: see text]) reaction. By combining the experimental data and simulated calculations, the modulation curve for the gamma ray was successfully obtained. A remarkably high polarization sensitivity was achieved, compatible with a reasonable detection efficiency. Based on the obtained results, a possible future gamma-ray polarimetery is discussed.
Collapse
Affiliation(s)
- S Go
- RIKEN Cluster for Pioneering Research, RIKEN, Wako, Saitama, Japan.
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan.
| | - Y Tsuzuki
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
- Department of Physics, The University of Tokyo, Tokyo, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Chiba, Japan
| | - H Yoneda
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
- Lehrstuhl für Astronomie, Fakultät für Physik und Astronomie, Institut für Theoretische Physik und Astrophysik, Julius-Maximilians-Universität Würzburg, Emil-Fischer-Str. 31, 97074, Würzburg, Germany
| | - Y Ichikawa
- Department of Physics, Kyushu University, Fukuoka, Japan
| | - T Ikeda
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
| | - N Imai
- Center for Nuclear Study, The University of Tokyo, Wako, Saitama, Japan
| | - K Imamura
- RIKEN Cluster for Pioneering Research, RIKEN, Wako, Saitama, Japan
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
| | - M Niikura
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
| | - D Nishimura
- Department of Natural Sciences, Tokyo City University, Tokyo, Japan
| | - R Mizuno
- Department of Physics, The University of Tokyo, Tokyo, Japan
| | - S Takeda
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Chiba, Japan
| | - H Ueno
- RIKEN Cluster for Pioneering Research, RIKEN, Wako, Saitama, Japan
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
| | - S Watanabe
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency, Kanagawa, Japan
| | - T Y Saito
- Center for Nuclear Study, The University of Tokyo, Wako, Saitama, Japan
- Atomic, Molecular, and Optical Physics Laboratory, RIKEN, Wako, Saitama, Japan
| | - S Shimoura
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
- Center for Nuclear Study, The University of Tokyo, Wako, Saitama, Japan
| | - S Sugawara
- Department of Natural Sciences, Tokyo City University, Tokyo, Japan
| | - A Takamine
- RIKEN Cluster for Pioneering Research, RIKEN, Wako, Saitama, Japan
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama, Japan
| | - T Takahashi
- Department of Physics, The University of Tokyo, Tokyo, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo, Chiba, Japan
| |
Collapse
|
2
|
Cubiss JG, Andreyev AN, Barzakh AE, Van Duppen P, Hilaire S, Péru S, Goriely S, Al Monthery M, Althubiti NA, Andel B, Antalic S, Atanasov D, Blaum K, Cocolios TE, Day Goodacre T, de Roubin A, Farooq-Smith GJ, Fedorov DV, Fedosseev VN, Fink DA, Gaffney LP, Ghys L, Harding RD, Huyse M, Imai N, Joss DT, Kreim S, Lunney D, Lynch KM, Manea V, Marsh BA, Martinez Palenzuela Y, Molkanov PL, Neidherr D, O'Neill GG, Page RD, Prosnyak SD, Rosenbusch M, Rossel RE, Rothe S, Schweikhard L, Seliverstov MD, Sels S, Skripnikov LV, Stott A, Van Beveren C, Verstraelen E, Welker A, Wienholtz F, Wolf RN, Zuber K. Deformation versus Sphericity in the Ground States of the Lightest Gold Isotopes. Phys Rev Lett 2023; 131:202501. [PMID: 38039485 DOI: 10.1103/physrevlett.131.202501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 08/02/2023] [Accepted: 09/18/2023] [Indexed: 12/03/2023]
Abstract
The changes in mean-squared charge radii of neutron-deficient gold nuclei have been determined using the in-source, resonance-ionization laser spectroscopy technique, at the ISOLDE facility (CERN). From these new data, nuclear deformations are inferred, revealing a competition between deformed and spherical configurations. The isotopes ^{180,181,182}Au are observed to possess well-deformed ground states and, when moving to lighter masses, a sudden transition to near-spherical shapes is seen in the extremely neutron-deficient nuclides, ^{176,177,179}Au. A case of shape coexistence and shape staggering is identified in ^{178}Au which has a ground and isomeric state with different deformations. These new data reveal a pattern in ground-state deformation unique to the gold isotopes, whereby, when moving from the heavy to light masses, a plateau of well-deformed isotopes exists around the neutron midshell, flanked by near-spherical shapes in the heavier and lighter isotopes-a trend hitherto unseen elsewhere in the nuclear chart. The experimental charge radii are compared to those from Hartree-Fock-Bogoliubov calculations using the D1M Gogny interaction and configuration mixing between states of different deformation. The calculations are constrained by the known spins, parities, and magnetic moments of the ground states in gold nuclei and show a good agreement with the experimental results.
Collapse
Affiliation(s)
- J G Cubiss
- School of Physics, Engineering and Technology, University of York, York, YO10 5DD, United Kingdom
| | - A N Andreyev
- School of Physics, Engineering and Technology, University of York, York, YO10 5DD, United Kingdom
- Advanced Science Research Center (ASRC), Japan Atomic Energy Agency, Tokai-mura, Japan
| | - A E Barzakh
- Affiliated with an institute covered by a cooperation agreement with CERN
| | - P Van Duppen
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
| | - S Hilaire
- Université Paris-Saclay, CEA, LMCE, 91680, Bruyères-le-Châtel, France
| | - S Péru
- Université Paris-Saclay, CEA, LMCE, 91680, Bruyères-le-Châtel, France
| | - S Goriely
- Institut d'Astronomie et d'Astrophysique, CP-226, Université Libre de Bruxelles, 1050 Brussels, Belgium
| | - M Al Monthery
- School of Physics, Engineering and Technology, University of York, York, YO10 5DD, United Kingdom
| | - N A Althubiti
- The University of Manchester, Department of Physics and Astronomy, Oxford Road, M13 9PL Manchester, United Kingdom
- Physics Department, College of Science, Jouf University, Sakakah, Kingdom of Saudi Arabia
| | - B Andel
- Department of Nuclear Physics and Biophysics, Comenius University in Bratislava, 84248 Bratislava, Slovakia
| | - S Antalic
- Department of Nuclear Physics and Biophysics, Comenius University in Bratislava, 84248 Bratislava, Slovakia
| | - D Atanasov
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- CERN, 1211, Geneva 23, Switzerland
| | - K Blaum
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - T E Cocolios
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
- The University of Manchester, Department of Physics and Astronomy, Oxford Road, M13 9PL Manchester, United Kingdom
| | - T Day Goodacre
- The University of Manchester, Department of Physics and Astronomy, Oxford Road, M13 9PL Manchester, United Kingdom
- CERN, 1211, Geneva 23, Switzerland
| | - A de Roubin
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | - G J Farooq-Smith
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
- The University of Manchester, Department of Physics and Astronomy, Oxford Road, M13 9PL Manchester, United Kingdom
| | - D V Fedorov
- Affiliated with an institute covered by a cooperation agreement with CERN
| | | | - D A Fink
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- CERN, 1211, Geneva 23, Switzerland
| | - L P Gaffney
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
- CERN, 1211, Geneva 23, Switzerland
| | - L Ghys
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
| | - R D Harding
- School of Physics, Engineering and Technology, University of York, York, YO10 5DD, United Kingdom
- CERN, 1211, Geneva 23, Switzerland
| | - M Huyse
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
| | - N Imai
- Center for Nuclear Study (CNS), Graduate School of Science The University of Tokyo, Japan
| | - D T Joss
- Department of Physics, University of Liverpool, Liverpool, L69 7ZE, United Kingdom
| | - S Kreim
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- CERN, 1211, Geneva 23, Switzerland
| | - D Lunney
- CSNSM-CNRS, Université de Paris Sud, 91400 Orsay, France
| | - K M Lynch
- The University of Manchester, Department of Physics and Astronomy, Oxford Road, M13 9PL Manchester, United Kingdom
- CERN, 1211, Geneva 23, Switzerland
| | - V Manea
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
| | | | - Y Martinez Palenzuela
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
- CERN, 1211, Geneva 23, Switzerland
| | - P L Molkanov
- Affiliated with an institute covered by a cooperation agreement with CERN
| | - D Neidherr
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt 64291, Germany
| | - G G O'Neill
- Department of Physics, University of Liverpool, Liverpool, L69 7ZE, United Kingdom
| | - R D Page
- Department of Physics, University of Liverpool, Liverpool, L69 7ZE, United Kingdom
| | - S D Prosnyak
- Affiliated with an institute covered by a cooperation agreement with CERN
| | - M Rosenbusch
- Institut für Physik, Universität Greifswald, 17487 Greifswald, Germany
| | - R E Rossel
- CERN, 1211, Geneva 23, Switzerland
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Mainz, D-55128, Germany
| | - S Rothe
- CERN, 1211, Geneva 23, Switzerland
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Mainz, D-55128, Germany
| | - L Schweikhard
- Institut für Physik, Universität Greifswald, 17487 Greifswald, Germany
| | - M D Seliverstov
- Affiliated with an institute covered by a cooperation agreement with CERN
| | - S Sels
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
| | - L V Skripnikov
- Affiliated with an institute covered by a cooperation agreement with CERN
| | - A Stott
- School of Physics, Engineering and Technology, University of York, York, YO10 5DD, United Kingdom
| | - C Van Beveren
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
| | - E Verstraelen
- KU Leuven, Instituut voor Kern- en Stralingsfysica, 3001 Leuven, Belgium
| | - A Welker
- CERN, 1211, Geneva 23, Switzerland
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden 01069, Germany
| | - F Wienholtz
- CERN, 1211, Geneva 23, Switzerland
- Institut für Physik, Universität Greifswald, 17487 Greifswald, Germany
| | - R N Wolf
- Max-Planck-Institut für Kernphysik, Saupfercheckweg 1, 69117 Heidelberg, Germany
- Institut für Physik, Universität Greifswald, 17487 Greifswald, Germany
| | - K Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Dresden 01069, Germany
| |
Collapse
|
3
|
Anker J, Pal SK, Kim-Schulze S, Wang H, Halperin R, Uzilov A, Imai N, Eikawa S, Saito T, Sebra R, Hahn NM, Patel M, Qi J, Xie H, Bhardwaj N, Gnjatic S, Galsky MD. Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer. J Immunother Cancer 2023; 11:e007613. [PMID: 37607770 PMCID: PMC10445357 DOI: 10.1136/jitc-2023-007613] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/04/2023] [Indexed: 08/24/2023] Open
Abstract
Cisplatin-based chemotherapy has been associated with durable disease control in a small subset of patients with metastatic urothelial cancer. However, the mechanistic basis for this phenomenon has remained elusive. Antitumor immunity may underlie these exceptional responders. In a phase II trial evaluating a phased schedule of gemcitabine and cisplatin followed by gemcitabine and cisplatin with ipilimumab for metastatic urothelial cancer, 4 of 36 patients achieved durable disease-free treatment-free survival (DDFTFS) and remain in remission over 5 years after enrolment on the study. We sought to identify the genomic and immunological mechanisms associated with functional cures of such patients. Whole exome sequencing was performed on pretreatment archival tumor tissue. Neoantigen prediction and ranking were performed using a novel pipeline. For a subset of patients with available biospecimens, selected peptides were tested for neoantigen-specific T cell reactivity in peripheral blood CD4+ and CD8+ T cells cultured with autologous antigen-presenting cells at baseline, postchemotherapy, and postchemotherapy and ipilimumab timepoints. Multiplex assays of serum protein analytes were also assessed at each time point. Serum proteomic analysis revealed that pretreatment, patients achieving DDFTFS demonstrated an immune activated phenotype with elevations in TH1 adaptive immunity, costimulatory molecules, and immune checkpoint markers. After combination cisplatin-based chemotherapy and ipilimumab treatment, DDFTFS patients again displayed enrichment for markers of adaptive immunity, as well as T cell cytotoxicity. CD27 was uniquely enriched in DDFTFS patients at all timepoints. Neoantigen reactivity was not detected in any patient at baseline or post two cycles of chemotherapy. Both CD4+ and CD8+ neoantigen-specific T cell reactivity was detected in two of two DDFTFS patients in comparison to zero of five non-DDFTFS patients after combination cisplatin-based chemotherapy and ipilimumab treatment. Antitumor immunity may underlie functional cures achieved in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy and immune checkpoint blockade. Probing the mechanistic basis for DDFTFS may facilitate the identification of biomarkers, therapeutic components, and optimal treatment sequences necessary to extend this ultimate goal to a larger subset of patients.
Collapse
Affiliation(s)
- Jonathan Anker
- Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Sumanta K Pal
- Department of Hematology and Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California, USA
| | - Seunghee Kim-Schulze
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | | | | | - Naoko Imai
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Shingo Eikawa
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Takuro Saito
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Osaka University School of Medicine Graduate School of Medicine, Suita, Osaka, Japan
| | - Robert Sebra
- Sema4, Branford, Connecticut, USA
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Noah M Hahn
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Manishkumar Patel
- Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Jingjing Qi
- Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Hui Xie
- Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Nina Bhardwaj
- Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Sacha Gnjatic
- Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Matthew D Galsky
- Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|
4
|
Yasutomi M, Christiaansen AF, Imai N, Martin-Orozco N, Forst CV, Chen G, Ueno H. CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells. Front Immunol 2022; 13:840457. [PMID: 35273617 PMCID: PMC8902812 DOI: 10.3389/fimmu.2022.840457] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 01/28/2022] [Indexed: 11/29/2022] Open
Abstract
Costimulation pathways play an essential role in T cell activation, differentiation, and regulation. CD155 expressed on antigen-presenting cells (APCs) interacts with TIGIT, an inhibitory costimulatory molecule, and CD226, an activating costimulatory molecule, on T cells. TIGIT and CD226 are expressed at varying levels depending on the T cell subset and activation state. T follicular helper cells in germinal centers (GC-Tfh) in human tonsils express high TIGIT and low CD226. However, the biological role of the CD155/TIGIT/CD226 axis in human Tfh cell biology has not been elucidated. To address this, we analyzed tonsillar CD4+ T cell subsets cultured with artificial APCs constitutively expressing CD155. Here we show that CD226 signals promote the early phase of Tfh cell differentiation in humans. CD155 signals promoted the proliferation of naïve CD4+ T cells and Tfh precursors (pre-Tfh) isolated from human tonsils and upregulated multiple Tfh molecules and decreased IL-2, a cytokine detrimental for Tfh cell differentiation. Blocking CD226 potently inhibited their proliferation and expression of Tfh markers. By contrast, while CD155 signals promoted the proliferation of tonsillar GC-Tfh cells, their proliferation required only weak CD226 signals. Furthermore, attenuating CD226 signals rather increased the expression of CXCR5, ICOS, and IL-21 by CD155-stimulated GC-Tfh cells. Thus, the importance of CD226 signals changes according to the differentiation stage of human Tfh cells and wanes in mature GC-Tfh cells. High TIGIT expression on GC-Tfh may play a role in attenuating the detrimental CD226 signals post GC-Tfh cell maturation.
Collapse
Affiliation(s)
- Motoko Yasutomi
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Allison F Christiaansen
- EMD Serono Research and Development Institute Inc. (The Healthcare Business of Merck KGaA, Darmstadt, Germany), Billerica, MA, United States
| | - Naoko Imai
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - Natalia Martin-Orozco
- EMD Serono Research and Development Institute Inc. (The Healthcare Business of Merck KGaA, Darmstadt, Germany), Billerica, MA, United States
| | - Christian V Forst
- Department of Genetics and Genomic Sciences, Department of Microbiology, The Icahn Institute for Data Science and Genomic Technology, New York, NY, United States
| | - Gang Chen
- EMD Serono Research and Development Institute Inc. (The Healthcare Business of Merck KGaA, Darmstadt, Germany), Billerica, MA, United States
| | - Hideki Ueno
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.,Department of Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.,ASHBi Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto, Japan
| |
Collapse
|
5
|
Imai N, Tawara I, Yamane M, Muraoka D, Shiku H, Ikeda H. CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. Cancer Sci 2020; 111:1958-1968. [PMID: 32304127 PMCID: PMC7293103 DOI: 10.1111/cas.14420] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Revised: 03/25/2020] [Accepted: 04/13/2020] [Indexed: 12/24/2022] Open
Abstract
Polyfunctionality/multifunctionality of effector T cells at the single cell level has been shown as an important parameter to predict the quality of T cell response and immunological control of infectious disease and malignancy. However, the fate of polyfunctional CD8+ CTLs and the factors that control the polyfunctionality of T cells remain largely unknown. Here we show that the acquisition of polyfunctionality on the initial stimulation is a sensitive immune correlate of CTL survival and memory formation. CD8+ T cells with high polyfunctionality, assessed with γ‐interferon and tumor necrosis factor‐α production and surface mobilization of the degranulation marker CD107a, showed enhanced Bcl‐2 expression, low apoptosis, and increased CD127highKLRG1low memory precursor phenotype. Consistent with these observations, CD8+ T cells were found to acquire high frequency of cells with polyfunctionality when stimulated in conditions known to enhance memory formation, such as the presence of CD4+ T cells, interleukin (IL)‐2, or IL‐21. Utilizing T‐cell receptor (TCR) transgenic mouse‐derived CD8+ T cells that express a TCR specific for a tumor‐derived neoantigen, we showed that polyfunctional tumor‐specific CTLs generated in the presence of CD4+ T cells showed long persistence in vivo and induced enhanced tumor regression when adoptively transferred into mice with progressing tumor. Acquisition of polyfunctionality thus impacts CTL survival and memory formation associated with immunological control of tumor.
Collapse
Affiliation(s)
- Naoko Imai
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.,Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Isao Tawara
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Makiko Yamane
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan
| | - Daisuke Muraoka
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.,Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Hiroshi Shiku
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan
| | - Hiroaki Ikeda
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.,Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| |
Collapse
|
6
|
Vaquero V, Jungclaus A, Aumann T, Tscheuschner J, Litvinova EV, Tostevin JA, Baba H, Ahn DS, Avigo R, Boretzky K, Bracco A, Caesar C, Camera F, Chen S, Derya V, Doornenbal P, Endres J, Fukuda N, Garg U, Giaz A, Harakeh MN, Heil M, Horvat A, Ieki K, Imai N, Inabe N, Kalantar-Nayestanaki N, Kobayashi N, Kondo Y, Koyama S, Kubo T, Martel I, Matsushita M, Million B, Motobayashi T, Nakamura T, Nakatsuka N, Nishimura M, Nishimura S, Ota S, Otsu H, Ozaki T, Petri M, Reifarth R, Rodríguez-Sánchez JL, Rossi D, Saito AT, Sakurai H, Savran D, Scheit H, Schindler F, Schrock P, Semmler D, Shiga Y, Shikata M, Shimizu Y, Simon H, Steppenbeck D, Suzuki H, Sumikama T, Symochko D, Syndikus I, Takeda H, Takeuchi S, Taniuchi R, Togano Y, Tsubota J, Wang H, Wieland O, Yoneda K, Zenihiro J, Zilges A. Fragmentation of Single-Particle Strength around the Doubly Magic Nucleus ^{132}Sn and the Position of the 0f_{5/2} Proton-Hole State in ^{131}In. Phys Rev Lett 2020; 124:022501. [PMID: 32004026 DOI: 10.1103/physrevlett.124.022501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 11/29/2019] [Indexed: 06/10/2023]
Abstract
Spectroscopic factors of neutron-hole and proton-hole states in ^{131}Sn and ^{131}In, respectively, were measured using one-nucleon removal reactions from doubly magic ^{132}Sn at relativistic energies. For ^{131}In, a 2910(50)-keV γ ray was observed for the first time and tentatively assigned to a decay from a 5/2^{-} state at 3275(50) keV to the known 1/2^{-} level at 365 keV. The spectroscopic factors determined for this new excited state and three other single-hole states provide first evidence for a strong fragmentation of single-hole strength in ^{131}Sn and ^{131}In. The experimental results are compared to theoretical calculations based on the relativistic particle-vibration coupling model and to experimental information for single-hole states in the stable doubly magic nucleus ^{208}Pb.
Collapse
Affiliation(s)
- V Vaquero
- Instituto de Estructura de la Materia, CSIC, E-28006 Madrid, Spain
| | - A Jungclaus
- Instituto de Estructura de la Materia, CSIC, E-28006 Madrid, Spain
| | - T Aumann
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
| | - J Tscheuschner
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - E V Litvinova
- Department of Physics, Western Michigan University, Kalamazoo, Michigan 49008-5252, USA
| | - J A Tostevin
- Department of Physics, University of Surrey, Guildford, Surrey GU2 7XH, United Kingdom
| | - H Baba
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - D S Ahn
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - R Avigo
- Dipartimento di Fisica dell'Università degli Studi di Milano, I-20133 Milano, Italy
- INFN, Sezione di Milano, I-20133 Milano, Italy
| | - K Boretzky
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
| | - A Bracco
- Dipartimento di Fisica dell'Università degli Studi di Milano, I-20133 Milano, Italy
- INFN, Sezione di Milano, I-20133 Milano, Italy
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
| | - F Camera
- Dipartimento di Fisica dell'Università degli Studi di Milano, I-20133 Milano, Italy
- INFN, Sezione di Milano, I-20133 Milano, Italy
| | - S Chen
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
- School of Physics and State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing 100871, China
| | - V Derya
- Institut für Kernphysik, Universität zu Köln, D-50937 Köln, Germany
| | - P Doornenbal
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - J Endres
- Institut für Kernphysik, Universität zu Köln, D-50937 Köln, Germany
| | - N Fukuda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - U Garg
- Department of Physics, University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - A Giaz
- Dipartimento di Fisica dell'Università degli Studi di Milano, I-20133 Milano, Italy
| | - M N Harakeh
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
- KVI-CART, Zernikelaan 25, NL-9747 AA Groningen, The Netherlands
| | - M Heil
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
| | - A Horvat
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - K Ieki
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - N Imai
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - N Inabe
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | | | - N Kobayashi
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - Y Kondo
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - S Koyama
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - T Kubo
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - I Martel
- Departamento de Fsica Aplicada, Universidad de Huelva, E-21071 Huelva, Spain
| | - M Matsushita
- Center for Nuclear Study, The University of Tokyo, Tokyo 113-0033, Japan
| | - B Million
- INFN, Sezione di Milano, I-20133 Milano, Italy
| | - T Motobayashi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - N Nakatsuka
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - M Nishimura
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Nishimura
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Ota
- Center for Nuclear Study, The University of Tokyo, Tokyo 113-0033, Japan
| | - H Otsu
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - M Petri
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - R Reifarth
- Institut für Kernphysik, Goethe University Frankfurt, D-60438 Frankfurt, Germany
| | - J L Rodríguez-Sánchez
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
- Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain
| | - D Rossi
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - H Sakurai
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - D Savran
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
| | - H Scheit
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - F Schindler
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
| | - P Schrock
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - D Semmler
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - Y Shiga
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, D-64291 Darmstadt, Germany
| | - D Steppenbeck
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Suzuki
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - T Sumikama
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - D Symochko
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - I Syndikus
- Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - H Takeda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Takeuchi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - R Taniuchi
- Department of Physics, The University of Tokyo, Tokyo 113-0033, Japan
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - H Wang
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - O Wieland
- INFN, Sezione di Milano, I-20133 Milano, Italy
| | - K Yoneda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - J Zenihiro
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - A Zilges
- Institut für Kernphysik, Universität zu Köln, D-50937 Köln, Germany
| |
Collapse
|
7
|
Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, Dudley JT, Brody JD, Jagannath S, Greenbaum B, Gnjatic S, Bhardwaj N, Parekh S. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clin Cancer Res 2019; 26:450-464. [PMID: 31857430 DOI: 10.1158/1078-0432.ccr-19-2309] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 09/19/2019] [Accepted: 11/15/2019] [Indexed: 12/30/2022]
Abstract
PURPOSE Somatic mutations in cancer cells can give rise to novel protein sequences that can be presented by antigen-presenting cells as neoantigens to the host immune system. Tumor neoantigens represent excellent targets for immunotherapy, due to their specific expression in cancer tissue. Despite the widespread use of immunomodulatory drugs and immunotherapies that recharge T and NK cells, there has been no direct evidence that neoantigen-specific T-cell responses are elicited in multiple myeloma. EXPERIMENTAL DESIGN Using next-generation sequencing data we describe the landscape of neo-antigens in 184 patients with multiple myeloma and successfully validate neoantigen-specific T cells in patients with multiple myeloma and support the feasibility of neoantigen-based therapeutic vaccines for use in cancers with intermediate mutational loads such as multiple myeloma. RESULTS In this study, we demonstrate an increase in neoantigen load in relapsed patients with multiple myeloma as compared with newly diagnosed patients with multiple myeloma. Moreover, we identify shared neoantigens across multiple patients in three multiple myeloma oncogenic driver genes (KRAS, NRAS, and IRF4). Next, we validate neoantigen T-cell response and clonal expansion in correlation with clinical response in relapsed patients with multiple myeloma. This is the first study to experimentally validate the immunogenicity of predicted neoantigens from next-generation sequencing in relapsed patients with multiple myeloma. CONCLUSIONS Our findings demonstrate that somatic mutations in multiple myeloma can be immunogenic and induce neoantigen-specific T-cell activation that is associated with antitumor activity in vitro and clinical response in vivo. Our results provide the foundation for using neoantigen targeting strategies such as peptide vaccines in future trials for patients with multiple myeloma.
Collapse
Affiliation(s)
- Deepak Perumal
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Naoko Imai
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alessandro Laganà
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, New York
| | - John Finnigan
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - David Melnekoff
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Violetta V Leshchenko
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alexander Solovyov
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Computational Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Deepu Madduri
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Ajai Chari
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Hearn Jay Cho
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Joel T Dudley
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Joshua D Brody
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Sundar Jagannath
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Benjamin Greenbaum
- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Computational Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Sacha Gnjatic
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Nina Bhardwaj
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Samir Parekh
- Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. .,Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|
8
|
Imai N, Hotta M, Shiraishi M, Suzuki T. Physical therapy using by craniocervical oscillating mechanical stimulation for chronic migraine. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
9
|
Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AHC, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ. Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunol Res 2019; 7:658-669. [PMID: 30745365 DOI: 10.1158/2326-6066.cir-18-0198] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2018] [Revised: 09/19/2018] [Accepted: 01/04/2019] [Indexed: 11/16/2022]
Abstract
Autologous stem cell transplant (autoSCT), the standard consolidation therapy for multiple myeloma, improves disease-free survival, but is not curative. This could be an ideal setting for immunologic therapy. However, the immune milieu is impaired after autoSCT. We hypothesized that autologous lymphocyte infusion would restore immune competence, allowing immunotherapies such as cancer vaccines to elicit tumor antigen-specific immunity in the setting of autoSCT. In this pilot study (NCT01380145), we investigated safety, immunologic, and clinical outcomes of autologous lymphocyte infusion combined with peri-autoSCT immunotherapy with recombinant MAGE-A3 (a multiple myeloma-associated antigen) and adjuvant. Thirteen patients with multiple myeloma undergoing autoSCT were enrolled. Autologous lymphocyte infusion and MAGE vaccination were well tolerated. Combination immunotherapy resulted in high-titer humoral immunity and robust, antigen-specific CD4+ T-cell responses in all subjects, and the responses persisted at least one year post-autoSCT. CD4+ T cells were polyfunctional and Th1-biased. CD8+ T-cell responses were elicited in 3 of 13 subjects. These cells recognized naturally processed MAGE-A3 antigen. Median progression-free survival was 27 months, and median overall survival was not reached, suggesting no differences from standard-of-care. In 4 of 8 subjects tested, MAGE-A protein expression was not detected by IHC in multiple myeloma cells at relapse, suggesting therapy-induced immunologic selection against antigen-expressing clones. These results demonstrated that autologous lymphocyte infusion augmentation of autoSCT confers a favorable milieu for immunotherapies such as tumor vaccines. This strategy does not require ex vivo manipulation of autologous lymphocyte products and is an applicable platform for further investigation into combination immunotherapies to treat multiple myeloma.
Collapse
Affiliation(s)
- Adam D Cohen
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
| | - Nikoletta Lendvai
- Memorial Sloan-Kettering Cancer Center, New York, New York.,Department of Medicine, Weill Medical College of Cornell University, New York, New York
| | - Sarah Nataraj
- Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York
| | - Naoko Imai
- Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York
| | | | - Ioanna Tsakos
- Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Adeeb Rahman
- Human Immune Monitoring Center, Icahn School of Medicine at Mt. Sinai, New York, New York
| | - Anna Huo-Chang Mei
- Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York
| | - Herman Singh
- Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York
| | - Katarzyna Zarychta
- Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York
| | - Seunghee Kim-Schulze
- Human Immune Monitoring Center, Icahn School of Medicine at Mt. Sinai, New York, New York
| | - Andrew Park
- Ludwig Institute for Cancer Research, New York, New York
| | - Ralph Venhaus
- Ludwig Institute for Cancer Research, New York, New York
| | | | - Sacha Gnjatic
- Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York.,Human Immune Monitoring Center, Icahn School of Medicine at Mt. Sinai, New York, New York
| | - Hearn J Cho
- Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York
| |
Collapse
|
10
|
Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, Heguy A, Imai N, Gnjatic S, Emerson RO, Zhou XK, Zhang T, Chachoua A, Demaria S. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 2018; 24:1845-1851. [PMID: 30397353 PMCID: PMC6286242 DOI: 10.1038/s41591-018-0232-2] [Citation(s) in RCA: 561] [Impact Index Per Article: 93.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Accepted: 09/04/2018] [Indexed: 12/20/2022]
Abstract
Focal radiation therapy enhances systemic responses to anti-CTLA-4 antibodies in preclinical studies and in some patients with melanoma1-3, but its efficacy in inducing systemic responses (abscopal responses) against tumors unresponsive to CTLA-4 blockade remained uncertain. Radiation therapy promotes the activation of anti-tumor T cells, an effect dependent on type I interferon induction in the irradiated tumor4-6. The latter is essential for achieving abscopal responses in murine cancers6. The mechanisms underlying abscopal responses in patients treated with radiation therapy and CTLA-4 blockade remain unclear. Here we report that radiation therapy and CTLA-4 blockade induced systemic anti-tumor T cells in chemo-refractory metastatic non-small-cell lung cancer (NSCLC), where anti-CTLA-4 antibodies had failed to demonstrate significant efficacy alone or in combination with chemotherapy7,8. Objective responses were observed in 18% of enrolled patients, and 31% had disease control. Increased serum interferon-β after radiation and early dynamic changes of blood T cell clones were the strongest response predictors, confirming preclinical mechanistic data. Functional analysis in one responding patient showed the rapid in vivo expansion of CD8 T cells recognizing a neoantigen encoded in a gene upregulated by radiation, supporting the hypothesis that one explanation for the abscopal response is radiation-induced exposure of immunogenic mutations to the immune system.
Collapse
Affiliation(s)
- Silvia C Formenti
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
| | | | - Encouse Golden
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
- Department of Radiation Oncology, University of California, San Francisco, CA, USA
| | - Benjamin Cooper
- Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
| | - Erik Wennerberg
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
| | - Claire Lhuillier
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
| | | | - Kent Friedman
- Department of Radiology, New York University School of Medicine, New York, NY, USA
| | - Lucas Ferrari de Andrade
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
- Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA
| | - Kai W Wucherpfennig
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
- Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA
| | - Adriana Heguy
- Department of Pathology, New York University School of Medicine, New York, NY, USA
- Genome Technology Center, Division of Advanced research Technologies, NYU Langone Health, New York, NY, USA
| | - Naoko Imai
- Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Sacha Gnjatic
- Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | | | - Xi Kathy Zhou
- Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, USA
| | - Tuo Zhang
- Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA
| | - Abraham Chachoua
- Department of Medicine, New York University School of Medicine, New York, NY, USA
| | - Sandra Demaria
- Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
| |
Collapse
|
11
|
Nagano M, Saito K, Kozuka Y, Shibusawa M, Imai N, Noro A, Kageyama Y, Mizuno T, Ogawa T, Katayama N. PD-L1 expression on circulating monocytes in patients with breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy427.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Jean K, Hamlet A, Dorigatti I, Gaythorpe K, Imai N, Cibrelus L, Benzler J, Garske T. Responding to yellow fever outbreaks in West and Central Africa: Rapid prioritization assessment for the pre-emptive vaccination campaigns. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.05.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
Krupar R, Pathak RR, Imai N, Genden E, Misiukiewicz K, Demicco EG, Patel J, Parikh F, Donovan M, Kim-Schulze S, Perner S, Posner M, Miles B, Gnjatic S, Sikora AG. Abstract 5639: Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Human papilloma virus associated oropharyngeal cancers (HPVOPC) account for about one third of OPC and express foreign viral antigens such as the E6 and E7 oncogenes, which are suitable for immune targeting. We performed a “window of opportunity” trial of patients undergoing standard-of-care transoral surgery for HPVOPC to assess the effect of the HPV16-E7 targeting vaccine ADXS11-001 on the intratumoral and systemic immune response. We reported, in a prior abstract, that 5 of 8 ADXS11-treated patients showed increased E6 or E7-specific IFN-γ responses post-treatment and 4/8 patients demonstrated increased CD8 and CD4 tumor infiltrating lymphocytes (TILs) after vaccination. In the present study, we profiled peripheral blood immunocyte populations (PBMCs) pre-vaccination, post-vaccination and post-surgery via multicolor flow cytometry in 8 patients. Clonal expansion and diversification of PBMCs and tumor TILs post-treatment were determined via T cell receptor (TCR) DNA sequencing and correlated to HPV antigen specific immune responses determined by ELISPOT as well as tumor immune profile determined by quantitative immunofluorescence. While peripheral CD8 cytotoxic T cell (CTL) levels remained constant over the course of the study, we observed trends towards their increased expression of LAG-3 (1.6 fold, p=0.0821) and PD-1 (1.6 fold, p=0.0748) 6 weeks post-surgery, consistent with activation. We did not observe statistically significant changes in levels of CD4 T helper cells, MDSC or Tregs, although a modest trend towards decreased CD8/MDSC ratio was observed post-surgery (0.5 fold, p=0.0864). Overall TCR diversity/clonality of PBMCs and TILs did not change. However the comparison of similarity between T cell repertoires of the tumor and PBMCs (Morisita's index) demonstrated an increase of expanded clones post-vaccination limited to TILs in 5/6 patients, indicating clonal expansion in ADXS11-treated patients. When we analyzed T cell repertoire changes in individual patients, 4 of 8 patients demonstrated expansion of specific TCR clones post-vaccination. The two patients with the greatest increase in number of expanded TCR clones among both, PBMCs and TILs, also had the strongest increase of E6 or E7-specific IFN-γ responses post-treatment, and also had strongly increased CD8 TILs. Our results demonstrate that immunomodulatory effects of ADXS11-001 on the local and peripheral immune response vary among patients, with 2/8 treated patients demonstrating evidence of an integrated adaptive immune response in blood and tumor, consistent with selective clonal expansion in the context of a vaccine-induced anti-tumor T cell response. Profiling of additional patients will permit more detailed analysis of ADXS11-induced immune modulation and impact on TCR diversity.
Citation Format: Rosemarie Krupar, Ravi R. Pathak, Naoko Imai, Eric Genden, Krzys Misiukiewicz, Elizabeth G. Demicco, Jigneshkumar Patel, Falguni Parikh, Michael Donovan, Seunghee Kim-Schulze, Sven Perner, Marshall Posner, Brett Miles, Sacha Gnjatic, Andrew G. Sikora. Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5639.
Collapse
Affiliation(s)
- Rosemarie Krupar
- 1Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Luebeck, Germany
| | - Ravi R. Pathak
- 2Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX
| | - Naoko Imai
- 3Division of Hematology and Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY
| | - Eric Genden
- 4Department of Otolaryngology, Mount Sinai School of Medicine, New York, NY
| | - Krzys Misiukiewicz
- 3Division of Hematology and Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY
| | | | - Jigneshkumar Patel
- 2Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX
| | - Falguni Parikh
- 2Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX
| | - Michael Donovan
- 5Division of Pathology, Mount Sinai School of Medicine, New York, NY
| | - Seunghee Kim-Schulze
- 3Division of Hematology and Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY
| | - Sven Perner
- 1Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Luebeck, Germany
| | - Marshall Posner
- 3Division of Hematology and Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY
| | - Brett Miles
- 4Department of Otolaryngology, Mount Sinai School of Medicine, New York, NY
| | - Sacha Gnjatic
- 3Division of Hematology and Medical Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY
| | - Andrew G. Sikora
- 6Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, New York, TX
| |
Collapse
|
14
|
Shimizu H, Kahl D, Yamaguchi H, Abe K, Beliuskina O, Cha SM, Chae KY, Chen AA, Ge Z, Hayakawa S, Imai N, Iwasa N, Kim A, Kim DH, Kim MJ, Kubono S, Kawag MS, Liang J, Moon JY, Nishimura S, Oka S, Park SY, Psaltis A, Teranishi T, Ueno Y, Yang L. Isomeric 26Al beam production with CRIB. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201818402013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
We performed an experiment to measure proton resonant elastic scattering of a mixed 26m,gAl beam with a thick target in inverse kinematics by using CNS RI beam sep-arator, located at RIKEN Nishina Center. It aimed to search for strong proton resonances and determine level properties of low spin-parity states in 27Si. Diagnosis of the 26mAl purity of the beam by annihilation radiation are discussed.
Collapse
|
15
|
Strano E, Mazzocco M, Boiano A, Boiano C, La Commara M, Manea C, Parascandolo C, Pierroutsakou D, Signorini C, Torresi D, Yamaguchi H, Kahl D, Acosta L, Di Meo P, Fernandez-Garcia J, Glodariu T, Grebosz J, Guglielmetti A, Imai N, Hirayama Y, Ishiyama H, Iwasa N, Jeong S, Jia H, Keeley N, Kim Y, Kimura S, Kubono S, Lay J, Lin C, Marquinez-Duran G, Marte I, Miyatake H, Mukai M, Nakao T, Nicoletto M, Pakou A, Rusek K, Sakaguchi Y, Sanchez-Benitez A, Sava T, Sgouros O, Stefanini C, Soramel F, Soukeras V, Stiliaris E, Stroe L, Teranishi T, Toniolo N, Wakabayashi Y, Watanabe Y, Yang L, Yang Y. 7Be and 8B reaction dynamics at Coulomb barrier energies. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201818402015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
We investigated the reaction dynamics induced by the 7Be,8B+208Pb collisions at energies around the Coulomb barrier. Charged particles originated by both the col- lisions were detected by means of 6 ΔE-Eres telescopes of a newly developed detector array. Experimental data were analysed within the framework of the Optical Model and the total reaction cross-sections were compared together and with the 6,7Li+208Pb colli-sion data. According to the preliminary results, 7Be nucleus reactivity is rather similar to the 7Li one whereas the 8B+208Pb total reaction cross section appears to be much larger than those measured for reactions induced by the other weakly-bound projectiles on the same target.
Collapse
|
16
|
Imai N, Shota I, Horiuchi K, Tasaki A, Yagi N, Konishi T, Serizawa M, Kobari M. Comparison of resting-state functional connectivity between women with chronic migraine and those with episodic migraine. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Takaki H, Imai N, Thomas CT, Yamakado K, Yarmohammadi H, Ziv E, Srimathveeravalli G, Sofocleous CT, Solomon SB, Erinjeri JP. Changes in peripheral blood T-cell balance after percutaneous tumor ablation. MINIM INVASIV THER 2017; 26:331-337. [PMID: 28417678 DOI: 10.1080/13645706.2017.1310737] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
PURPOSE To evaluate the changes in T-cell balance in peripheral blood following percutaneous tumor ablation. MATERIAL AND METHODS Patients underwent thermal ablation including radiofrequency (n = 9) and microwave ablation (n = 5), or cryoablation (n = 5). Target tumors were located in the lung (n = 7), soft tissue (n = 5), liver (n = 4), and bone (n = 3). Patient peripheral blood samples were collected before and within 14 days after ablation. Peripheral blood populations of cytotoxic T-cells (CTL), type-1 (Th1) and type-2 helper T-cells (Th2), and regulatory T-cells (Treg) were measured using flow cytometry. Changes in CTL/Treg and Th1/Th2 ratios before and after ablation therapy were compared using paired t-tests. RESULTS Peripheral blood CTL population (27.5 ± 2.1% to 30.2 ± 2.5%, p < .03) and CTL/Treg ratios (18.8 ± 3.7% to 21.6 ± 3.6%, p < .05) increased significantly after ablation. Although a significant increase in CTL/Treg ratios was found after heat-based ablation (18.0 ± 4.4% to 21.6 ± 4.7%, p < .02), it remained unchanged after cryoablation (21.0 ± 7.0% to 21.5 ± 4.3%, p = .92). Th1/Th2 ratio (13.7 ± 3.0% to 17.2 ± 3.5%, p = .12) remained unchanged after ablation. CONCLUSION Ablation therapy alters the T-cell balance by increasing the systemic CTL/Treg, ratio. Heat-based ablation might be a more effective approach than cryoablation to enhance systemic anti-tumor immunity.
Collapse
Affiliation(s)
- Haruyuki Takaki
- a Department of Radiology , Hyogo College of Medicine , Nishinomiya , Japan
| | - Naoko Imai
- b Department of Hematology and Oncology , Icahn School of Medicine at Mount Sinai , New York , NY , USA
| | - Contessa T Thomas
- c Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA
| | - Koichiro Yamakado
- a Department of Radiology , Hyogo College of Medicine , Nishinomiya , Japan
| | - Hooman Yarmohammadi
- c Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA
| | - Etay Ziv
- c Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA
| | | | | | - Stephen B Solomon
- c Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA
| | - Joseph P Erinjeri
- c Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA
| |
Collapse
|
18
|
Yoshikawa M, Miyata Y, Mizuguchi M, Imai N, Hojo H, Ichimura M, Kariya T, Katanuma I, Nakashima Y, Minami R, Shidara H, Yamaguchi Y, Shima Y, Ohno Y, Yaguchi F, Imai T. Use of a Gold Neutral Beam Probe to Study Fluctuation Suppression During Potential Formation in the GAMMA 10 Tandem Mirror. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a9492] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Yoshikawa
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Miyata
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - M. Mizuguchi
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - N. Imai
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - H. Hojo
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - M. Ichimura
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Kariya
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - I. Katanuma
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Nakashima
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - R. Minami
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - H. Shidara
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Yamaguchi
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Shima
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Ohno
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - F. Yaguchi
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| | - T. Imai
- University of Tsukuba, Plasma Research Center, Tsukuba, Ibaraki 305-8577, Japan
| |
Collapse
|
19
|
Kuroda R, Nakada T, Ojima T, Serizawa M, Imai N, Yagi N, Tasaki A, Aoki M, Oiwa T, Ogane T, Mochizuki K, Kobari M, Miyajima H. The TriAGe+ Score for Vertigo or Dizziness: A Diagnostic Model for Stroke in the Emergency Department. J Stroke Cerebrovasc Dis 2017; 26:1144-1153. [PMID: 28256416 DOI: 10.1016/j.jstrokecerebrovasdis.2017.01.009] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 12/13/2016] [Accepted: 01/13/2017] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Vertigo or dizziness is a common occurrence, but it remains a challenging symptom when encountered in the emergency department (ED). A diagnostic score for stroke with high accuracy is therefore required. METHODS A single-center observational study (498 patients) was conducted. The predictor variables were derived from a multivariate logistic regression analysis with Akaike information criterion. The outcome was the occurrence of stroke. We evaluated the utility of a new diagnostic score (TriAGe+) and compared it with the ABCD2 score. RESULTS The cohorts included 498 patients (147 with stroke [29.4%]). Eight variables were included: triggers, atrial fibrillation, male gender, blood pressure ≥140/90 mm Hg, brainstem or cerebellar dysfunction, focal weakness or speech impairment, dizziness, and no history of vertigo or dizziness or labyrinth or vestibular disease. We derived the TriAGe+ score from these variables. In the cohort, the prevalence of stroke increased significantly using the diagnostic score: 5.9% for a score of 0-4; 9.1% for 5-7; 24.7% for 8-9; and 57.3% for 10-17. At a cutoff value of 10 points, the sensitivity of the score was 77.5%, the specificity was 72.1%, and the positive likelihood ratio was 3.2. When the cutoff was defined as 5 points, the score obtained a high sensitivity (96.6%) with a good negative likelihood ratio (.15). The new score outperformed the ABCD2 score for the occurrence of stroke (C statistic, .818 versus .726; P < .001). CONCLUSIONS The TriAGe+ score can identify the occurrence of stroke in patients with vertigo or dizziness presenting to the ED.
Collapse
Affiliation(s)
- R Kuroda
- Department of Neurology, Hamamatsu University School of Medicine, Shizuoka, Japan.
| | - T Nakada
- Critical Care Medical Center, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - T Ojima
- Department of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan
| | - M Serizawa
- Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - N Imai
- Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - N Yagi
- Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - A Tasaki
- Departments of Neurology, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - M Aoki
- Critical Care Medical Center, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - T Oiwa
- Critical Care Medical Center, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - T Ogane
- Critical Care Medical Center, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - K Mochizuki
- Critical Care Medical Center, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - M Kobari
- Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan
| | - H Miyajima
- Department of Neurology, Hamamatsu University School of Medicine, Shizuoka, Japan
| |
Collapse
|
20
|
Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ. IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun 2017; 8:14607. [PMID: 28233863 PMCID: PMC5333095 DOI: 10.1038/ncomms14607] [Citation(s) in RCA: 109] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Accepted: 01/16/2017] [Indexed: 12/18/2022] Open
Abstract
Genetic evolution that occurs during cancer progression enables tumour heterogeneity, thereby fostering tumour adaptation, therapeutic resistance and metastatic potential. Immune responses are known to select (immunoedit) tumour cells displaying immunoevasive properties. Here we address the role of IFN-γ in mediating the immunoediting process. We observe that, in several mouse tumour models such as HA-expressing 4T1 mammary carcinoma cells, OVA-expressing EG7 lymphoma cells and CMS5 MCA-induced fibrosarcoma cells naturally expressing mutated extracellular signal-regulated kinase (ERK) antigen, the action of antigen-specific cytotoxic T cell (CTL) in vivo results in the emergence of resistant cancer cell clones only in the presence of IFN-γ within the tumour microenvironment. Moreover, we show that exposure of tumours to IFN-γ-producing antigen-specific CTLs in vivo results in copy-number alterations (CNAs) associated with DNA damage response and modulation of DNA editing/repair gene expression. These results suggest that enhanced genetic instability might be one of the mechanisms by which CTLs and IFN-γ immunoedits tumours, altering their immune resistance as a result of genetic evolution. T cell mediated anti-tumour immune responses result in the emergence of an immune-resistant population in a process called immunoediting. Here, the authors show that immunoediting is associated with an increase in genomic rearrangements of tumour cells that requires both cytotoxic T cells and IFNγ exposure.
Collapse
Affiliation(s)
- Kazuyoshi Takeda
- Division of Cell Biology, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan.,Department of Biofunctional Micribiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan.,Department of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.,Cancer Immunology Program, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, 3002 Victoria, Australia
| | - Masafumi Nakayama
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai 980-8578, Japan.,Department of Immunobiology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai 980-8575, Japan
| | - Yoshihiro Hayakawa
- Cancer Immunology Program, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, 3002 Victoria, Australia.,Division of Pathogenic Biochemistry, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Sugitani 2630, Toyama 930-0194, Japan
| | - Yuko Kojima
- Laboratory of Morphology and Image Analysis, Biomedical Research Center, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
| | - Hiroaki Ikeda
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.,Department of Oncology, Nagasaki University Graduate School of Biomedical Science, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Naoko Imai
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.,Department of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, New York 10029, USA
| | - Kouetsu Ogasawara
- Department of Immunobiology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai 980-8575, Japan
| | - Ko Okumura
- Department of Biofunctional Micribiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan.,Department of Immunology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.,Atopy (Allergy) Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan
| | - David M Thomas
- Cancer Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia
| | - Mark J Smyth
- Cancer Immunology Program, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, 3002 Victoria, Australia.,Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, 4006 Queensland, Australia.,School of Medicine, University of Queensland, Herston, 4006 Queensland, Australia
| |
Collapse
|
21
|
Tasaki M, Saito K, Nakagawa Y, Imai N, Ito Y, Aoki T, Kamimura M, Narita I, Tomita Y, Takahashi K. Acquired Downregulation of Donor-Specific Antibody Production After ABO-Incompatible Kidney Transplantation. Am J Transplant 2017; 17:115-128. [PMID: 27343838 DOI: 10.1111/ajt.13937] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Revised: 05/31/2016] [Accepted: 06/21/2016] [Indexed: 01/25/2023]
Abstract
The mechanism of long-term B cell immunity against donor blood group antigens in recipients who undergo ABO-incompatible (ABOi) living-donor kidney transplantation (LKTx) is unknown. To address this question, we evaluated serial anti-A and anti-B antibody titers in 50 adult recipients. Donor-specific antibody titers remained low (≤1:4) in 42 recipients (84%). However, antibodies against nondonor blood group antigens were continuously produced in recipients with blood type O. We stimulated recipients' peripheral blood mononuclear cells in vitro to investigate whether B cells produced antibodies against donor blood group antigens in the absence of graft adsorption in vivo. Antibodies in cell culture supernatant were measured using specific enzyme-linked immunosorbent assays (ELISAs). Thirty-five healthy volunteers and 57 recipients who underwent ABO-compatible LKTx served as controls. Antibody production in vitro against donor blood group antigens by cells from ABOi LKTx patients was lower than in the control groups. Immunoglobulin deposits were undetectable in biopsies of grafts of eight recipients with low antibody titers (≤1:4) after ABOi LKTx. One patient with blood type A1 who received a second ABOi LKTx from a type B donor did not produce B-specific antibodies. These findings suggest diminished donor-specific antibody production function in the setting of adult ABOi LKTx.
Collapse
Affiliation(s)
- M Tasaki
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - K Saito
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Y Nakagawa
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - N Imai
- Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Y Ito
- Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - T Aoki
- Division of Transfusion Medicine and Regenerative Medicine, Bioscience Medical Center, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - M Kamimura
- Division of Transfusion Medicine and Regenerative Medicine, Bioscience Medical Center, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - I Narita
- Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Y Tomita
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - K Takahashi
- Division of Urology, Department of Regenerative & Transplant Medicine, Niigata Graduate School of Medical and Dental Sciences, Niigata, Japan.,Niigata Prefecture Organ Transplant Promotion Foundation, Tokyo, Japan
| |
Collapse
|
22
|
Commara ML, Mazzocco M, Boiano A, Boiano C, Manea C, Parascandolo C, Pierroutsakou D, Signorini C, Strano E, Torresi D, Yamaguchi H, Kahl D, Meo PD, Grebosz J, Imai N, Hirayama Y, Ishiyama H, Iwasa N, Jeong S, Jia H, Kim Y, Kimura S, Kubono S, Lin C, Miyatake H, Mukai M, Nakao T, Nicoletto M, Sakaguchi Y, Sánchez-Benítez A, Soramel F, Teranishi T, Wakabayashi Y, Watanabe Y, Yang L, Yang Y. 8B + 208Pb Elastic Scattering at Coulomb Barrier Energies. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201716300032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Yamaguchi H, Kahl D, Hayakawa S, Yang L, Shimizu H, Sakaguchi Y, Abe K, Nakao T, Suhara T, Iwasa N, Kim A, Kim D, Cha S, Kwag M, Lee J, Lee E, Chae K, Wakabayashi Y, Imai N, Kitamura N, Lee P, Moon J, Lee K, Akers C, Jung H, Duy N, Khiem L, Lee C, Hashimoto T, Kubono S, Kawabata T, Teranishi T, Kwon Y, Binh D. Nuclear astrophysics projects at the low-energy RI beam separator CRIB. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201716501056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Kahl D, Shimizu H, Yamaguchi H, Abe K, Beliuskina O, Cha SM, Chae KY, Chen AA, Ge Z, Hayakawa S, Imai N, Iwasa N, Kim A, Kim DH, Kim MJ, Kubono S, Kwag MS, Liang J, Moon JY, Nishimura S, Oka S, Park SY, Psaltis A, Teranishi T, Ueno Y, Yang L. Isomer beam elastic scattering: 26mAl(p, p) for astrophysics. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201716501030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Imai N, Shibagaki Y, Yazawa M, Kitajima K, Nakazawa R, Sasaki H, Chikaraishi T. Follow-up rates of living kidney donor in Japan: A single center study. Indian J Nephrol 2016; 26:423-426. [PMID: 27942174 PMCID: PMC5131381 DOI: 10.4103/0971-4065.172229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Long-term follow-up of kidney donors is needed not only for the individual donor's benefit but also to establish analyzable databases to improve the selection criteria for future donors. We collected data including the date of transplantation, the date of the last follow-up, donor's age, sex, their relationship to the recipient, renal function, proteinuria, and the prevalence of hypertension. Of 124 donors, 52 donors were not being followed up. The mean duration of follow-up was 4.3 ± 3.6 years. Follow-up rates were 83.9%, 74.6%, and 59.2% at 1 year, 2 years, and 5 years postdonation, respectively. Of those not being followed up, 75% dropped out. Follow-up rates did not differ between parent and spouse donors 5 years (57.1% vs. 71.4%; P = 0.4) postdonation. Similarly, follow-up rates at 5 years did not differ between donors aged 60 years or older and those younger than 60 (57.5% vs. 61.3%; P = 0.6). Of 72 donors being followed up, 75.0% had estimated glomerular filtration rate of <60 mL/min/1.73 m2, 8.3% had proteinuria, and 41.7% had hypertension requiring medication. There is a limitation to the endeavor of each transplant center to follow-up all their donors. Long-term donor follow-up in Japan requires a national registration system and mandates transplant center participation.
Collapse
Affiliation(s)
- N Imai
- Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - Y Shibagaki
- Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - M Yazawa
- Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - K Kitajima
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - R Nakazawa
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - H Sasaki
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - T Chikaraishi
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| |
Collapse
|
26
|
Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S. Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification. Int J Oncol 2016; 50:129-140. [DOI: 10.3892/ijo.2016.3786] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Accepted: 11/14/2016] [Indexed: 11/06/2022] Open
|
27
|
Kyogoku N, Ikeda H, Tsuchikawa T, Abiko T, Fujiwara A, Maki T, Yamamura Y, Ichinokawa M, Tanaka K, Imai N, Miyahara Y, Kageyama S, Shiku H, Hirano S. Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel. Oncol Lett 2016; 12:4493-4504. [PMID: 28105158 PMCID: PMC5228337 DOI: 10.3892/ol.2016.5253] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Accepted: 09/29/2016] [Indexed: 12/24/2022] Open
Abstract
A phase I+II clinical trial of vaccination with MAGE-A4 protein complexed with cholesteryl pullulan melanoma antigen gene-A4 nanogel (CHP-MAGE-A4) is currently underway in patients with MAGE-A4-expressing cancer. In the present study, the primary phase I endpoint was to test the safety of the administration of 300 µg CHP-MAGE-A4 with and without OK-432. Another aim of the study was to clarify the details of the specific humoral immune response to vaccination. The 9 patients enrolled for phase I were vaccinated 6 times, once every 2 weeks: 3 patients with 100 µg and 3 patients with 300 µg CHP-MAGE-A4, and 3 patients with 300 µg CHP-MAGE-A4 plus 0.5 clinical units of OK-432. Toxicities were assessed using Common Terminology Criteria for Adverse Events v3.0. Clinical response was evaluated by modified Response Evaluation Criteria in Solid Tumours. Immunological monitoring of anti-MAGE-A4-specific antibodies was performed by ELISA of pre- and post-vaccination patient sera. The 6 vaccinations produced no severe adverse events. Stable disease was assessed in 4/9 patients. Anti-MAGE-A4 total immunoglobulin (Ig)G titers increased in 7/9 patients. Efficacious anti-MAGE-A4 IgG1, 2 and 3 antibody responses were observed in 7/9 patients. Among them, positive conversions to T helper 2 (Th2)-type antibody responses (IgG4 and IgE) were observed after frequent vaccination in 4/7 patients. The Th2 conversion was possibly associated with undesirable clinical observations, including progressive disease and the appearance of a new relapse lesion. The present study suggested that frequent vaccinations activated a Th2-dominant status in the cancer patients. The identification of a time-dependent IgG subclass and IgE antibody production during vaccination protocols may be a useful surrogate marker indicating a potentially undesirable change of the immunological environment for an effective antitumor immune response in cancer patients.
Collapse
Affiliation(s)
- Noriaki Kyogoku
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Hiroaki Ikeda
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
| | - Takahiro Tsuchikawa
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Takehiro Abiko
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Aki Fujiwara
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Takehiro Maki
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Yoshiyuki Yamamura
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Masaomi Ichinokawa
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Kimitaka Tanaka
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| | - Naoko Imai
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
| | - Yoshihiro Miyahara
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
| | - Shinichi Kageyama
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
| | - Hiroshi Shiku
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
| | - Satoshi Hirano
- Department of Gastroenterological Surgery II, Division of Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-8638, Japan
| |
Collapse
|
28
|
Nanda VGY, Peng W, Hwu P, Davies MA, Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA, Croce CM, Mancini R, Spranger S, Gajewski TF, Wang Y, Ferrone S, Vanpouille-Box C, Wennerberg E, Pilones KA, Formenti SC, Demaria S, Tang H, Wang Y, Fu YX, Dummer R, Puzanov I, Tarhini A, Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sanders C, Kirkwood JM, Chen THT, Maurer M, Korman AJ, Zarour HM, Stroncek DF, Huber V, Rivoltini L, Thurin M, Rau T, Lugli A, Pagès F, Camarero J, Sancho A, Jommi C, de Coaña YP, Wolodarski M, Yoshimoto Y, Gentilcore G, Poschke I, Masucci GV, Hansson J, Kiessling R, Scognamiglio G, Sabbatino F, Marino FZ, Anniciello AM, Cantile M, Cerrone M, Scala S, D’alterio C, Ianaro A, Cirin G, Liguori G, Bott G, Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Testori A, Lorigan P, Sosman JA, Flaherty KT, Yue H, Coleman S, Caro I, Hauschild A, McArthur GA, Sznol M, Callahan MK, Kluger H, Postow MA, Gordan R, Segal NH, Rizvi NA, Lesokhin A, Atkins MB, Burke MM, Ralabate A, Rivera A, Kronenberg SA, Agunwamba B, Ruisi M, Horak C, Jiang J, Wolchok J, Ascierto PA, Liszkay G, Maio M, Mandalà M, Demidov L, Stoyakovskiy D, Thomas L, de la Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Wongchenko M, Chang I, Koralek DO, Rooney I, Yan Y, Dréno B, Sullivan R, Patel M, Hodi S, Amaria R, Boasberg P, Wallin J, He X, Cha E, Richie N, Ballinger M, Smith DC, Bauer TM, Wasser JS, Luke JJ, Balmanoukian AS, Kaufman DR, Zhao Y, Maleski J, Leopold L, Gangadhar TC, Long GV, Michielin O, VanderWalde A, Andtbacka RHI, Cebon J, Fernandez E, Malvehy J, Olszanski AJ, Gause C, Chen L, Chou J, Stephen Hodi F, Brady B, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Lebbé C, Ny L, Chacon M, Queirolo P, Loquai C, Cheema P, Berrocal A, Eizmendi KM, Bar-Sela G, Horak C, Hardy H, Weber JS, Grob JJ, Marquez-Rodas I, Schmidt H, Briscoe K, Baurain JF, Wolchok JD, Pinto R, De Summa S, Garrisi VM, Strippoli S, Azzariti A, Guida G, Guida M, Tommasi S, Jacquelot N, Enot D, Flament C, Pitt JM, Vimond N, Blattner C, Yamazaki T, Roberti MP, Vetizou M, Daillere R, Poirier-Colame V, la Semeraro M, Caignard A, Slingluff CL, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Umansky V, Eggermont A, Zitvogel L, Anna P, Marco T, Stefania S, Francesco M, Mariaelena C, Gabriele M, Antonio AP, Franco S, Roberti MP, Enot DP, Semeraro M, Jégou S, Flores C, Chen THT, Kwon BS, Anderson AC, Borg C, Aubin F, Ayyoub M, De Presbiteris AL, Cordaro FG, Camerlingo R, Fratangelo F, Mozzillo N, Pirozzi G, Patriarca EJ, Caputo E, Motti ML, Falcon R, Miceli R, Capone M, Madonna G, Mallardo D, Carrier MV, Panza E, De Cicco P, Armogida C, Ercolano G, Botti G, Cirino G, Sandru A, Blank M, Balatoni T, Olasz J, Farkas E, Szollar A, Savolt A, Godeny M, Csuka O, Horvath S, Eles K, Shoenfeld Y, Kasler M, Costantini S, Capone F, Moradi F, Berglund P, Leandersson K, Linnskog R, Andersson T, Prasad CP, Nigro CL, Lattanzio L, Wang H, Proby C, Syed N, Occelli M, Cauchi C, Merlano M, Harwood C, Thompson A, Crook T, Bifulco K, Ingangi V, Minopoli M, Ragone C, Pessi A, Mannavola F, D’Oronzo S, Felici C, Tucci M, Doronzo A, Silvestris F, Ferretta A, Guida S, Maida I, Cocco T, Passarelli A, Quaresmini D, Franzese O, Palermo B, Di Donna C, Sperduti I, Foddai M, Stabile H, Gismondi A, Santoni A, Nisticò P, Sponghini AP, Platini F, Marra E, Rondonotti D, Alabiso O, Fierro MT, Savoia P, Stratica F, Quaglino P, Di Monta G, Corrado C, Di Marzo M, Ugo M, Di Cecilia ML, Nicola M, Fusciello C, Marra A, Guarrasi R, Baldi C, Russo R, Di Giulio G, Faiola V, Zeppa P, Pepe S, Gambale E, Carella C, Di Paolo A, De Tursi M, Marra L, De Murtas F, Sorrentino V, Voinea S, Panaitescu E, Bolovan M, Stanciu A, Cinca S, Botti C, Aquino G, Anniciello A, Fortes C, Mastroeni S, Caggiati A, Passarelli F, Zappalà A, Capuano M, Bono R, Nudo M, Marino C, Michelozzi P, De Biasio V, Battarra VC, Formenti S, Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL, Gnjatic S, Nataraj S, Imai N, Rahman A, Jungbluth AA, Pan L, Venhaus R, Park A, Lehmann FF, Lendvai N, Cohen AD, Cho HJ, Daniel S, Hirsh V. Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016; 14:65. [PMID: 27461275 PMCID: PMC4965835 DOI: 10.1186/s12967-016-0791-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
MELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies K2 Non-mutational adaptive changes in melanoma cells exposed to BRAF and MEK inhibitors help the establishment of drug resistance Gennaro Ciliberto, Luigi Fattore, Debora Malpicci, Luigi Aurisicchio, Paolo Antonio Ascierto, Carlo M. Croce, Rita Mancini K3 Tumor-intrinsic beta-catenin signaling mediates tumor-immune avoidance Stefani Spranger, Thomas F. Gajewski K4 Intracellular tumor antigens as a source of targets of antibody-based immunotherapy of melanoma Yangyang Wang, Soldano Ferrone Combination therapies K5 Harnessing radiotherapy to improve responses to immunotherapy in cancer Claire Vanpouille-Box, Erik Wennerberg, Karsten A. Pilones, Silvia C. Formenti, Sandra Demaria K6 Creating a T cell-inflamed tumor microenvironment overcomes resistance to checkpoint blockade Haidong Tang, Yang Wang, Yang-Xin Fu K7 Biomarkers for treatment decisions? Reinhard Dummer K8 Combining oncolytic therapies in the era of checkpoint inhibitors Igor Puzanov K9 Immune checkpoint blockade for melanoma: should we combine or sequence ipilimumab and PD-1 antibody therapy? Michael A. Postow News in immunotherapy K10 An update on adjuvant and neoadjuvant therapy for melanom Ahmad Tarhini K11 Targeting multiple inhibitory receptors in melanoma Joe-Marc Chauvin, Ornella Pagliano, Julien Fourcade, Zhaojun Sun, Hong Wang, Cindy Sanders, John M. Kirkwood, Tseng-hui Timothy Chen, Mark Maurer, Alan J. Korman, Hassane M. Zarour K12 Improving adoptive immune therapy using genetically engineered T cells David F. Stroncek Tumor microenvironment and biomarkers K13 Myeloid cells and tumor exosomes: a crosstalk for assessing immunosuppression? Veronica Huber, Licia Rivoltini K14 Update on the SITC biomarker taskforce: progress and challenges Magdalena Thurin World-wide immunoscore task force: an update K15 The immunoscore in colorectal cancer highlights the importance of digital scoring systems in surgical pathology Tilman Rau, Alessandro Lugli K16 The immunoscore: toward an integrated immunomonitoring from the diagnosis to the follow up of cancer’s patients Franck Pagès Economic sustainability of melanoma treatments: regulatory, health technology assessment and market access issues K17 Nivolumab, the regulatory experience in immunotherapy Jorge Camarero, Arantxa Sancho K18 Evidence to optimize access for immunotherapies Claudio Jommi ORAL PRESENTATIONS Molecular and immuno-advances O1 Ipilimumab treatment results in CD4 T cell activation that is concomitant with a reduction in Tregs and MDSCs Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V. Masucci, Johan Hansson, Rolf Kiessling O2 Evaluation of prognostic and therapeutic potential of COX-2 and PD-L1 in primary and metastatic melanoma Giosuè Scognamiglio, Francesco Sabbatino, Federica Zito Marino, Anna Maria Anniciello, Monica Cantile, Margherita Cerrone, Stefania Scala, Crescenzo D’alterio, Angela Ianaro, Giuseppe Cirino, Paolo Antonio Ascierto, Giuseppina Liguori, Gerardo Botti O3 Vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma: final overall survival results of the BRIM-3 study Paul B. Chapman, Caroline Robert, James Larkin, John B. Haanen, Antoni Ribas, David Hogg, Omid Hamid, Paolo Antonio Ascierto, Alessandro Testori, Paul Lorigan, Reinhard Dummer, Jeffrey A. Sosman, Keith T. Flaherty, Huibin Yue, Shelley Coleman, Ivor Caro, Axel Hauschild, Grant A. McArthur O4 Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma Mario Sznol, Margaret K. Callahan, Harriet Kluger, Michael A. Postow, RuthAnn Gordan, Neil H. Segal, Naiyer A. Rizvi, Alexander Lesokhin, Michael B. Atkins, John M. Kirkwood, Matthew M. Burke, Amanda Ralabate, Angel Rivera, Stephanie A. Kronenberg, Blessing Agunwamba, Mary Ruisi, Christine Horak, Joel Jiang, Jedd Wolchok Combination therapies O5 Efficacy and correlative biomarker analysis of the coBRIM study comparing cobimetinib (COBI) + vemurafenib (VEM) vs placebo (PBO) + VEM in advanced BRAF-mutated melanoma patients (pts) Paolo A. Ascierto, Grant A. McArthur, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stoyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Matthew Wongchenko, Ilsung Chang, Daniel O. Koralek, Isabelle Rooney, Yibing Yan, Antoni Ribas, Brigitte Dréno O6 Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma Ryan Sullivan, Omid Hamid, Manish Patel, Stephen Hodi, Rodabe Amaria, Peter Boasberg, Jeffrey Wallin, Xian He, Edward Cha, Nicole Richie, Marcus Ballinger, Patrick Hwu O7 Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma Thomas F. Gajewski, Omid Hamid, David C. Smith, Todd M. Bauer, Jeffrey S. Wasser, Jason J. Luke, Ani S. Balmanoukian, David R. Kaufman, Yufan Zhao, Janet Maleski, Lance Leopold, Tara C. Gangadhar O8 Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma Reinhard Dummer, Georgina V. Long, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert H.I. Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J. Olszanski, Thomas F. Gajewski, John M. Kirkwood, Christine Gause, Lisa Chen, David R. Kaufman, Jeffrey Chou, F. Stephen Hodi News in immunotherapy O9 Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066 Victoria Atkinson, Paolo A. Ascierto, Georgina V. Long, Benjamin Brady, Caroline Dutriaux, Michele Maio, Laurent Mortier, Jessica C. Hassel, Piotr Rutkowski, Catriona McNeil, Ewa Kalinka-Warzocha, Celeste Lebbé, Lars Ny, Matias Chacon, Paola Queirolo, Carmen Loquai, Parneet Cheema, Alfonso Berrocal, Karmele Mujika Eizmendi, Luis De La Cruz-Merino, Gil Bar-Sela, Christine Horak, Joel Jiang, Helene Hardy, Caroline Robert O10 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Georgina V. Long, Jeffrey S. Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Reinhard Dummer, Caroline Robert, Ivan Marquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F. Stephen Hodi, Jedd D. Wolchok Tumor microenvironment and biomarkers O11 New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma Rosamaria Pinto, Simona De Summa, Vito Michele Garrisi, Sabino Strippoli, Amalia Azzariti, Gabriella Guida, Michele Guida, Stefania Tommasi O12 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma and response to ipilimumab Nicolas Jacquelot, David Enot, Caroline Flament, Jonathan M. Pitt, Nadège Vimond, Carolin Blattner, Takahiro Yamazaki, Maria-Paula Roberti, Marie Vetizou, Romain Daillere, Vichnou Poirier-Colame, Michaëla Semeraro, Anne Caignard, Craig L Slingluff Jr, Federica Sallusto, Sylvie Rusakiewicz, Benjamin Weide, Aurélien Marabelle, Holbrook Kohrt, Stéphane Dalle, Andréa Cavalcanti, Guido Kroemer, Anna Maria Di Giacomo, Michaele Maio, Phillip Wong, Jianda Yuan, Jedd Wolchok, Viktor Umansky, Alexander Eggermont, Laurence Zitvogel O13 Serum levels of PD1- and CD28-positive exosomes before Ipilimumab correlate with therapeutic response in metastatic melanoma patients Passarelli Anna, Tucci Marco, Stucci Stefania, Mannavola Francesco, Capone Mariaelena, Madonna Gabriele, Ascierto Paolo Antonio, Silvestris Franco O14 Immunological prognostic factors in stage III melanomas María Paula Roberti, Nicolas Jacquelot, David P Enot, Sylvie Rusakiewicz, Michaela Semeraro, Sarah Jégou, Camila Flores, Lieping Chen, Byoung S. Kwon, Ana Carrizossa Anderson, Caroline Robert, Christophe Borg, Benjamin Weide, François Aubin, Stéphane Dalle, Michele Maio, Jedd D. Wolchok, Holbrook Kohrt, Maha Ayyoub, Guido Kroemer, Aurélien Marabelle, Andréa Cavalcanti, Alexander Eggermont, Laurence Zitvogel POSTER PRESENTATIONS Molecular and immuno-advances P1 Human melanoma cells resistant to B-RAF and MEK inhibition exhibit
mesenchymal-like features Anna Lisa De Presbiteris, Fabiola Gilda Cordaro, Rosa Camerlingo, Federica Fratangelo, Nicola Mozzillo, Giuseppe Pirozzi, Eduardo J. Patriarca, Paolo A. Ascierto, Emilia Caputo P2 Anti-proliferative and pro-apoptotic effect of ABT888 on melanoma cell lines and its potential role in the treatment of melanoma resistant to B-RAF inhibitors Federica Fratangelo, Rosa Camerlingo, Emilia Caputo, Maria Letizia Motti, Rosaria Falcone, Roberta Miceli, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, Maria Vincenza Carriero, Giuseppe Pirozzi and Paolo Antonio Ascierto P3 Involvement of the L-cysteine/CSE/H2S pathway in human melanoma progression Elisabetta Panza, Paola De Cicco, Chiara Armogida, Giuseppe Ercolano, Rosa Camerlingo, Giuseppe Pirozzi, Giosuè Scognamiglio, Gerardo Botti, Giuseppe Cirino, Angela Ianaro P4 Cancer stem cell antigen revealing pattern of antibody variable region genes were defined by immunoglobulin repertoire analysis in patients with malignant melanoma Beatrix Kotlan, Gabriella Liszkay, Miri Blank, Timea Balatoni, Judit Olasz, Emil Farkas, Andras Szollar, Akos Savolt, Maria Godeny, Orsolya Csuka, Szabolcs Horvath, Klara Eles, Yehuda Shoenfeld and Miklos Kasler P5 Upregulation of Neuregulin-1 expression is a hallmark of adaptive response to BRAF/MEK inhibitors in melanoma Debora Malpicci, Luigi Fattore, Susan Costantini, Francesca Capone, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto P6 HuR positively regulates migration of HTB63 melanoma cells Farnaz Moradi, Pontus Berglund, Karin Leandersson, Rickard Linnskog, Tommy Andersson, Chandra Prakash Prasad P7 Prolyl 4- (C-P4H) hydroxylases have opposing effects in malignant melanoma: implication in prognosis and therapy Cristiana Lo Nigro, Laura Lattanzio, Hexiao Wang, Charlotte Proby, Nelofer Syed, Marcella Occelli, Carolina Cauchi, Marco Merlano, Catherine Harwood, Alastair Thompson, Tim Crook P8 Urokinase receptor antagonists: novel agents for the treatment of melanoma Maria Letizia Motti, Katia Bifulco, Vincenzo Ingangi, Michele Minopoli, Concetta Ragone, Federica Fratangelo, Antonello Pessi, Gennaro Ciliberto, Paolo Antonio Ascierto, Maria Vincenza Carriero P9 Exosomes released by melanoma cell lines enhance chemotaxis of primary tumor cells Francesco Mannavola, Stella D’Oronzo, Claudia Felici, Marco Tucci, Antonio Doronzo, Franco Silvestris P10 New insights in mitochondrial metabolic reprogramming in melanoma Anna Ferretta, Gabriella Guida, Stefania Guida, Imma Maida, Tiziana Cocco, Sabino Strippoli, Stefania Tommasi, Amalia Azzariti, Michele Guida P11 Lenalidomide restrains the proliferation in melanoma cells through a negative regulation of their cell cycle Stella D’Oronzo, Anna Passarelli, Claudia Felici, Marco Tucci, Davide Quaresmini, Franco Silvestris Combination therapies P12 Chemoimmunotherapy elicits polyfunctional anti-tumor CD8 + T cells depending on the activation of an AKT pathway sustained by ICOS Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, MariaLaura Foddai, Helena Stabile, Angela Gismondi, Angela Santoni, Paola Nisticò P13 Favourable toxicity profile of combined BRAF and MEK inhibitors in metastatic melanoma patients Andrea P. Sponghini, Francesca Platini, Elena Marra, David Rondonotti, Oscar Alabiso, Maria T. Fierro, Paola Savoia, Florian Stratica, Pietro Quaglino P14 Electrothermal bipolar vessel sealing system dissection reduces seroma output or time to drain removal following axillary and ilio-inguinal node dissection in melanoma patients: a pilot study Di Monta Gianluca, Caracò Corrado, Di Marzo Massimiliano, Marone Ugo, Di Cecilia Maria Luisa, Mozzillo Nicola News in immunotherapy P15 Clinical and immunological response to ipilimumab in a metastatic melanoma patient with HIV infection Francesco Sabbatino, Celeste Fusciello1, Antonio Marra, Rosario Guarrasi, Carlo Baldi, Rosa Russo, Di Giulio Giovanni, Vincenzo Faiola, Pio Zeppa, Stefano Pepe P16 Immunotherapy and hypophysitis: a case report Elisabetta Gambale, Consiglia Carella, Alessandra Di Paolo, Michele De Tursi Tumor microenvironment and biomarkers P17 New immuno- histochemical markers for the differential diagnosis of atypical melanocytic lesions with uncertain malignant potential Laura Marra, Giosuè Scognamiglio, Monica Cantile, Margherita Cerrone, Fara De Murtas, Valeria Sorrentino, Anna Maria Anniciello, Gerardo Botti P18 Utility of simultaneous measurement of three serum tumor markers in melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P19 The significance of various cut-off levels of melanoma inhibitory activity in evaluation of cutaneous melanoma patients Angela Sandru, Silviu Voinea, Eugenia Panaitescu, Madalina Bolovan, Adina Stanciu, Sabin Cinca P20 The long noncoding RNA HOTAIR is associated to metastatic progression of melanoma and it can be identified in the blood of patients with advanced disease Chiara Botti, Giosuè Scognamiglio, Laura Marra, Gabriella Aquino, Rosaria Falcone, Annamaria Anniciello, Paolo Antonio Ascierto, Gerardo Botti, Monica Cantile Other P21 The effect of Sentinel Lymph Node Biopsy in melanoma mortality: timing of dissection Cristina Fortes, Simona Mastroeni, Alessio Caggiati, Francesca Passarelli, Alba Zappalà, Maria Capuano, Riccardo Bono, Maurizio Nudo, Claudia Marino, Paola Michelozzi P22 Epidemiological survey on related psychopathology in melanoma Valeria De Biasio, Vincenzo C. Battarra IMMUNOTHERAPY BRIDGE KEYNOTE SPEAKER PRESENTATIONS Immunotherapy beyond melanoma K19 Predictor of response to radiation and immunotherapy Silvia Formenti K20 Response and resistance to PD-1 pathway blockade: clues from the tumor microenvironment Maria Libera Ascierto, Tracee L. McMiller, Alan E. Berger, Ludmila Danilova, Robert A. Anders, George J. Netto, Haiying Xu, Theresa S. Pritchard, Jinshui Fan, Chris Cheadle, Leslie Cope, Charles G. Drake, Drew M. Pardoll, Janis M. Taube and Suzanne L. Topalian K21 Combination immunotherapy with autologous stem cell transplantation, protein immunization, and PBMC reinfusion in myeloma patients Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Adeeb Rahman, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Andrew Park, Frédéric F. Lehmann, Nikoletta Lendvai, Adam D. Cohen, and Hearn J. Cho K22 Anti-cancer immunity despite T cell “exhaustion” Speiser Daniel Immunotherapy in oncology (I-O): data from clinical trial K23 The Checkpoint Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) Vera Hirsh
Collapse
|
29
|
Krupar R, Imai N, Miles B, Genden E, Misiukiewicz K, Saenger Y, Demicco EG, Patel J, Herrera PC, Parikh F, Donovan M, Kim-Schulze S, Posner M, Gnjatic S, Sikora AG. Abstract LB-095: HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity. Immunology 2016. [DOI: 10.1158/1538-7445.am2016-lb-095] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
30
|
Nakahama H, Okada M, Miyazaki M, Imai N, Yokokawa T, Kubori S. Distinct Responses of Interleukin-6 and Other Laboratory Parameters to Treatment in a Patient with Polyarteritis Nodosa—A Case Report. Angiology 2016; 43:512-6. [PMID: 1350713 DOI: 10.1177/000331979204300610] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The authors describe a patient in whom the serum levels of interleukin-6 (IL-6) and other laboratory parameters were monitored. The IL-6 and C-reac tive protein (CRP) levels, which were extremely high before treatment, declined rapidly with administration of prednisolone. Rheumatoid factor, IgG, and platelets count declined more gradually. Thus, determination of the serum IL-6 level might be useful in diagnosing and monitoring polyarteritis nodosa.
Collapse
Affiliation(s)
- H Nakahama
- Department of Medicine, Kansai Rosai Hospital, Hyogo, Japan
| | | | | | | | | | | |
Collapse
|
31
|
Mazzocco M, Boiano A, Boiano C, La Commara M, Manea C, Parascandolo C, Pierroutsakou D, Signorini C, Strano E, Torresi D, Yamaguchi H, Kahl D, Acosta L, Di Meo P, Fernandez-Garcia J, Glodariu T, Grebosz J, Guglielmetti A, Imai N, Hirayama Y, Ishiyama H, Iwasa N, Jeong S, Jia H, Keeley N, Kim Y, Kimura S, Kubono S, Lay J, Lin C, Marquinez-Duran G, Martel I, Miyatake H, Mukai M, Nakao T, Nicoletto M, Pakou A, Rusek K, Sakaguchi Y, Sánchez-Benítez A, Sava T, Sgouros O, Stefanini C, Soramel F, Soukeras V, Stiliaris E, Stroe L, Teranishi T, Toniolo N, Wakabayashi Y, Watanabe Y, Yang L, Yang Y. 7Be- and8B-reaction dynamics at Coulomb barrier energies. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611706006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
32
|
Takaki H, Imai N, Contessa TT, Srimathveeravalli G, Covey AM, Getrajdman GI, Brown KT, Solomon SB, Erinjeri JP. Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization. J Vasc Interv Radiol 2016; 27:1561-8. [PMID: 27084711 DOI: 10.1016/j.jvir.2016.01.150] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2015] [Revised: 01/29/2016] [Accepted: 01/29/2016] [Indexed: 12/14/2022] Open
Abstract
PURPOSE To evaluate changes in T-cell populations in peripheral blood after bland hepatic artery embolization (HAE). MATERIALS AND METHODS Bland HAE was performed in 12 patients to treat primary (n = 5) or metastatic (n = 7) liver tumors, using microspheres and polyvinyl alcohol (n = 8) or microspheres alone (n = 4). Patient peripheral blood samples were collected within 1 month before HAE, within 1 week after HAE (early period after HAE), and 2-8 weeks after HAE (follow-up period). Peripheral blood populations of cytotoxic T lymphocytes, CD4(+) T cells, type 1 helper T cells (Th1) and type 2 helper T cells (Th2), and regulatory T cells (Treg) were evaluated using flow cytometry. Changes in T-cell populations before and after bland HAE were compared using paired t tests. RESULTS Peripheral blood CD4(+) T-cell populations decreased significantly in the early period after HAE (44.0% ± 2.2 to 34.4% ± 3.6, P < .01) and in the follow-up period (44.0% ± 2.2 to 36.3% ± 3.0, P < .01). Among the individual CD4(+) T-cell subtypes, Treg (2.5% ± 0.3 to 1.7% ± 0.2, P < .02) and Th1 (8.1% ± 1.8 to 5.6% ± 1.6, P < .02) decreased significantly in the early period after HAE only. The presence of extrahepatic disease was associated with decreasing Treg (P < .04). CONCLUSIONS After HAE, the peripheral blood T-cell environment is changed with decreases in Treg and Th1.
Collapse
Affiliation(s)
- Haruyuki Takaki
- Department of Radiology, Hyogo Collage of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
| | - Naoko Imai
- Division of Hematology/Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Thomas T Contessa
- Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | | | - Anne M Covey
- Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - George I Getrajdman
- Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Karen T Brown
- Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Stephen B Solomon
- Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Joseph P Erinjeri
- Interventional Radiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| |
Collapse
|
33
|
Imai N, Shirai S, Yasuda T, Shibagaki Y, Kimura K. Long-term prognosis of IgA nephropathy presenting with minimal or no proteinuria: A single center experience. Indian J Nephrol 2016; 26:107-12. [PMID: 27051134 PMCID: PMC4795425 DOI: 10.4103/0971-4065.157010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The long-term prognosis of patients with IgA nephropathy (IgAN) who present with preserved renal function and minimal proteinuria is not well described. We investigated the long-term outcomes of IgAN patients with an apparently benign presentation and evaluated prognostic factors for renal survival and clinical remission. We studied Japanese patients with biopsy-proven IgAN who had an estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 and proteinuria <0.5 g/day at the time of renal biopsy. The renal biopsies were reviewed using the Oxford classification. Twenty patients met the inclusion criteria. At diagnosis, the median eGFR (interquartile range) was 76.8 (65.2–91.1) mL/min/1.73 m2, and the median proteinuria level was 0.31 (0.16–0.39) g/day. Only one patient had an increase in serum creatinine of over 50% and no patient progressed to end-stage renal disease. The 15-year renal survival rate was 93.8%. Clinical remission was observed in 9 (45%) patients. Baseline proteinuria was the only factor significantly associated with the absence of clinical remission. The long-term prognosis of Japanese patients with IgAN who presents with minor urinary abnormalities and preserved renal function is excellent.
Collapse
Affiliation(s)
- N Imai
- Division of Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - S Shirai
- Division of Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - T Yasuda
- Division of Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - Y Shibagaki
- Division of Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - K Kimura
- Department of Internal Medicine, Tokyo Takanawa Hospital, Tokyo, Japan
| |
Collapse
|
34
|
Hirayama Y, Miyatake H, Watanabe Y, Imai N, Ishiyama H, Jeong S, Jung H, Oyaizu M, Mukai M, Kimura S, Sonoda T, Wada M, Kim Y, Huyse M, Kudryavtsev Y, Van Duppen P. Beta-decay spectroscopy of r-process nuclei around N= 126. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201610908001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Imai N, Tsuji T, Altorki NK, Kuo PY, Perumal D, Parekh S, Gnjatic S. Abstract B062: Differences of transcriptional profiles between long-term tolerized and memory CD4 T cells. Cancer Immunol Res 2016. [DOI: 10.1158/2326-6074.cricimteatiaacr15-b062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
It is well known that immunological adjuvants improve antigen-specific immune responses to cancer vaccines. We previously reported a clinical trial in non-small cell lung cancer where half of the patients received a cycle of 4 vaccines every 3 weeks with recombinant MAGEA3 protein alone in the absence of adjuvant, while the other half were vaccinated with MAGEA3 protein administered in adjuvant AS02B containing saponin and TLR4-ligand Monophosphoryl Lipid A. Results showed that vaccination without adjuvant led to very limited or no humoral and T cell immune responses to MAGEA3, while vaccine with adjuvant elicited robust humoral and CD4 T cell responses. Two to three years later, patients received a second cycle of vaccination, but this time with AS02B adjuvant for everyone. Remarkably, patients initially vaccinated without adjuvant still failed to mount immune responses even after 4 vaccines with adjuvant, exhibiting a tolerized phenotype, while remaining patients had a typical recall memory response reaching a plateau of high antibody and CD4 T cell levels after a single injection. This data suggested that the initial environment during priming dictates subsequent long-term capacity of CD4 T cells to expand and produce cytokines. While long-term tolerized CD4 T cells were induced in patients primed without adjuvant, in contrast to long-term memory CD4 T cells in patients vaccinated with adjuvant throughout, markers associated with T cell responsiveness vs. tolerance remain unclear. Here, we assessed antigen-specific cells using RNASeq analyses to elucidate at the transcriptional level mechanisms associated with qualitative differences in the CD4 T cell repertoire
We applied a sensitive method based on CD154 upregulation to detect and sort MAGEA3-specific CD4 T cells throughout the study, including even rare precursors present at baseline, from two patients representative of tolerized vs. memory profile respectively. Unexpectedly, we found that the number of CD154-expressing cells after MAGEA3 in vitro restimulation were highly increased in both patients after the first vaccine injection, but durably reduced thereafter in the tolerized patient, while still increasing in the responder patient. To characterize differences in transcriptional profiles, MAGEA3 specific CD4 T cells were subjected to RNASeq at baseline and after the 1st and 2nd immunization. Sorted MAGEA3 specific CD4 T cells were non-specifically expanded, and restimulated with MAGEA3, followed by RNA isolation and deep sequencing by RNASeq. A total of ~16,000 individual genes were found transcribed in all samples, and many were related to expected CD4 T cell characteristics. When expression levels of all genes were considered together in unsupervised principal component analysis, there was a remarkable difference in profiles between the two patients. While the responder had a consistent shift in gene transcript post-vaccine compared to baseline, the tolerized patient had a transient shift in genes expressed by MAGEA3-specific CD4 T cells after one vaccine, which was abolished and returned to a profile closer to baseline after the 2nd vaccine. We identified a set of 413 genes with differential expression profiles between tolerized and responder patients over early vaccination time points. These genes can be further classified according to whether they increase or decrease specifically in the tolerized or in the responder patient, when comparing baseline to 1st vaccine to 2nd vaccine, and by their constitutive vs. inducible nature following antigen stimulation. Immune-related genes were heavily predominant within this subset, and we found an array of cytokines and checkpoint molecules that we propose as candidates for a tolerance signature. These results could be useful for early prediction of vaccine efficacy and patient benefit in future immunotherapy trials.
Citation Format: Naoko Imai, Takemasa Tsuji, Nasser K. Altorki, Pei-Yu Kuo, Deepak Perumal, Samir Parekh, Sacha Gnjatic. Differences of transcriptional profiles between long-term tolerized and memory CD4 T cells. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B062.
Collapse
Affiliation(s)
- Naoko Imai
- 1Icahn School of Medicine at Mount Sinai, New York, NY,
| | - Takemasa Tsuji
- 2Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY,
| | | | - Pei-Yu Kuo
- 1Icahn School of Medicine at Mount Sinai, New York, NY,
| | | | - Samir Parekh
- 1Icahn School of Medicine at Mount Sinai, New York, NY,
| | - Sacha Gnjatic
- 1Icahn School of Medicine at Mount Sinai, New York, NY,
| |
Collapse
|
36
|
Watanabe YX, Kim YH, Jeong SC, Hirayama Y, Imai N, Ishiyama H, Jung HS, Miyatake H, Choi S, Song JS, Clement E, de France G, Navin A, Rejmund M, Schmitt C, Pollarolo G, Corradi L, Fioretto E, Montanari D, Niikura M, Suzuki D, Nishibata H, Takatsu J. Pathway for the Production of Neutron-Rich Isotopes around the N=126 Shell Closure. Phys Rev Lett 2015; 115:172503. [PMID: 26551108 DOI: 10.1103/physrevlett.115.172503] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Indexed: 06/05/2023]
Abstract
Absolute cross sections for isotopically identified products formed in multinucleon transfer in the (136)Xe+(198)Pt system at ∼8 MeV/nucleon are reported. The isotopic distributions obtained using a large acceptance spectrometer demonstrated the production of the "hard-to-reach" neutron-rich isotopes for Z<78 around the N=126 shell closure far from stability. The main contribution to the formation of these exotic nuclei is shown to arise in collisions with a small kinetic energy dissipation. The present experimental finding corroborates for the first time recent predictions that multinucleon transfer reactions would be the optimum method to populate and characterize neutron-rich isotopes around N=126 which are crucial for understanding both astrophysically relevant processes and the evolution of "magic" numbers far from stability.
Collapse
Affiliation(s)
- Y X Watanabe
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - Y H Kim
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
- Institute for Nuclear and Particle Astrophysics, Seoul National University, Seoul 08826, Korea
| | - S C Jeong
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - Y Hirayama
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - N Imai
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H Ishiyama
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H S Jung
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - H Miyatake
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - S Choi
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
- Institute for Nuclear and Particle Astrophysics, Seoul National University, Seoul 08826, Korea
| | - J S Song
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
- Institute for Nuclear and Particle Astrophysics, Seoul National University, Seoul 08826, Korea
- Institute for Basic Science, Daejeon 34047, Korea
| | - E Clement
- Grand Accélérateur National d'Ions Lourds (GANIL), F-14076 Caen Cedex 5, France
| | - G de France
- Grand Accélérateur National d'Ions Lourds (GANIL), F-14076 Caen Cedex 5, France
| | - A Navin
- Grand Accélérateur National d'Ions Lourds (GANIL), F-14076 Caen Cedex 5, France
| | - M Rejmund
- Grand Accélérateur National d'Ions Lourds (GANIL), F-14076 Caen Cedex 5, France
| | - C Schmitt
- Grand Accélérateur National d'Ions Lourds (GANIL), F-14076 Caen Cedex 5, France
| | - G Pollarolo
- Dipartimento di Fisica Teorica, Università di Torino, and Istituto Nazionale di Fisica Nucleare, I-10125 Torino, Italy
| | - L Corradi
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro, I-35020 Legnaro, Italy
| | - E Fioretto
- Istituto Nazionale di Fisica Nucleare, Laboratori Nazionali di Legnaro, I-35020 Legnaro, Italy
| | - D Montanari
- Dipartimento di Fisica, Università di Padova, and Istituto Nazionale di Fisica Nucleare, I-35131 Padova, Italy
| | - M Niikura
- Institut de Physique Nucléaire (IPN), IN2P3-CNRS, F-91406 Orsay Cedex, France
| | - D Suzuki
- Institut de Physique Nucléaire (IPN), IN2P3-CNRS, F-91406 Orsay Cedex, France
| | - H Nishibata
- Department of Physics, Osaka University, Osaka 560-0043, Japan
| | - J Takatsu
- Department of Physics, Osaka University, Osaka 560-0043, Japan
| |
Collapse
|
37
|
Gnjatic S, Nataraj S, Imai N, Jungbluth AA, Pan L, Venhaus R, Fellague-Chebra R, Gruselle O, Cohen A, Lendvai N, Cho HJ. Abstract LB-116: Strong MAGE-A3-specific humoral and cellular immune responses in multiple myeloma patients receiving MAGE-A3 protein immunotherapy and peripheral blood lymphocyte reconstitution. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-lb-116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
MAGE-A3 is an immunogenic tumor-associated antigen expressed in multiple myeloma (MM) patients and conferring poor prognosis, making it a rational target for immunotherapy. Recombinant MAGE-A3 protein was administered in AS15 immunostimulant (containing MPL, QS-21, and CpG 7909) to 13 MM patients pre- and post-autologous stem cell transplant (ASCT) coupled with infusion of vaccine-primed autologous peripheral blood lymphocytes (PBL) early post-ASCT (NCT01380145). All patients had MAGE-A+ myeloma cells at baseline and had an acceptable safety profile during immunotherapy.
Robust antibody responses against MAGE-A3 (assessed by ELISA) were induced in all 13 subjects, with high antibody titers (1:10^4-10^6) that persisted to at least 1-year post-ASCT. Subclass analysis demonstrated a prevalence of IgG1 and IgG3. Epitope mapping identified 7 distinct epitopes clustering in hydrophilic regions of MAGE-A3.
Peripheral blood T cell responses were evaluated in 8 subjects by IFNγ-ELISpot after in vitro re-stimulation with MAGE-A3 overlapping peptide pools. All patients quickly developed strong MAGE-A3-specific CD4 responses post-vaccination and ASCT, persisting 1-year post-ASCT. Intracellular cytokine staining confirmed polyfunctional, Th1-biased CD4 T cell responses. One patient developed CD8 responses against MAGE-A3 that recognized naturally processed antigen.
To date, 6 patients relapsed and 1 died of progressive MM, with no notable difference in cytogenetics or antibody titers compared to non-progressors. MAGE-A expression was assessed by immunohistochemistry in relapse bone marrow biopsies, and interestingly, 4/6 were negative.
MAGE-A3 protein-based immunotherapy and PBL reconstitution is generally well tolerated, feasible, and induces antibody and Th1-biased CD4 T cell responses, but only rare CD8 responses, in the setting of ASCT for MM. Cellular immune assessments are ongoing. The magnitudes of antibody and CD4 responses appear greater than those seen historically with older immunostimulant formulations of MAGE-A3 in other cancers, despite significant immune compromise after ASCT, suggesting a benefit from the new AS15 immunostimulant formulation, or from immunization and autologous PBL transfer in the peri-ASCT setting, or both. The frequent loss of MAGE-A3 expression in relapsing patients implies antigen-specific immune selective pressure, and suggests that combination strategies aimed at limiting immune escape should be investigated.
Funding Sources: GlaxoSmithKline Biologicals SA, Ludwig Institute for Cancer Research, Cancer Research Institute.
Citation Format: Sacha Gnjatic, Sarah Nataraj, Naoko Imai, Achim A. Jungbluth, Linda Pan, Ralph Venhaus, Rafik Fellague-Chebra, Olivier Gruselle, Adam Cohen, Nikoletta Lendvai, Hearn J. Cho. Strong MAGE-A3-specific humoral and cellular immune responses in multiple myeloma patients receiving MAGE-A3 protein immunotherapy and peripheral blood lymphocyte reconstitution. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-116. doi:10.1158/1538-7445.AM2015-LB-116
Collapse
Affiliation(s)
| | | | - Naoko Imai
- 1Mt. Sinai Icahn School of Medicine, New York, NY
| | | | - Linda Pan
- 3Ludwig Institute for Cancer Research, New York, NY
| | | | | | | | - Adam Cohen
- 5University of Pennsylvania, Philadelphia, PA
| | | | - Hearn J. Cho
- 1Mt. Sinai Icahn School of Medicine, New York, NY
| |
Collapse
|
38
|
Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clin Cancer Res 2015; 21:2268-77. [PMID: 25855804 DOI: 10.1158/1078-0432.ccr-14-1559] [Citation(s) in RCA: 111] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Accepted: 02/19/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE Preparative lymphodepletion, the temporal ablation of the immune system, has been reported to promote persistence of transferred cells along with increased rates of tumor regression in patients treated with adoptive T-cell therapy. However, it remains unclear whether lymphodepletion is indispensable for immunotherapy with T-cell receptor (TCR) gene-engineered T cells. EXPERIMENTAL DESIGN We conducted a first-in-man clinical trial of TCR gene-transduced T-cell transfer in patients with recurrent MAGE-A4-expressing esophageal cancer. The patients were given sequential MAGE-A4 peptide vaccinations. The regimen included neither lymphocyte-depleting conditioning nor administration of IL2. Ten patients, divided into 3 dose cohorts, received T-cell transfer. RESULTS TCR-transduced cells were detected in the peripheral blood for 1 month at levels proportional to the dose administered, and in 5 patients they persisted for more than 5 months. The persisting cells maintained ex vivo antigen-specific tumor reactivity. Despite the long persistence of the transferred T cells, 7 patients exhibited tumor progression within 2 months after the treatment. Three patients who had minimal tumor lesions at baseline survived for more than 27 months. CONCLUSIONS These results suggest that TCR-engineered T cells created by relatively short-duration in vitro culture of polyclonal lymphocytes in peripheral blood retained the capacity to survive in a host. The discordance between T-cell survival and tumor regression suggests that multiple mechanisms underlie the benefits of preparative lymphodepletion in adoptive T-cell therapy.
Collapse
Affiliation(s)
- Shinichi Kageyama
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan.
| | - Hiroaki Ikeda
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan
| | - Yoshihiro Miyahara
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan
| | - Naoko Imai
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan
| | | | - Kanako Saito
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
| | - Sahoko Sugino
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan
| | - Shugo Ueda
- Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
| | | | | | | | - Kohshi Ohishi
- Blood Transfusion Service, Mie University Hospital, Mie, Japan
| | - Taizo Shiraishi
- Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan
| | | | | | | | | | | | | | | | | | - Naoyuki Katayama
- Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan
| | - Hiroshi Shiku
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Mie, Japan.
| |
Collapse
|
39
|
Ikeda H, Ueno H, Kawamura A, Imai N, Okamoto S, Mineno J, Takesako K, Shiku H. Tumor-specific donor lymphocyte infusion therapy with allogeneic T cells utilizing novel retrovirus vector silencing endogenous TCR expression. J Immunother Cancer 2014. [PMCID: PMC4288585 DOI: 10.1186/2051-1426-2-s3-p20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
40
|
Imai N. EHMTI-0069. The low prevalence of “forehead and facial flushing” and “sensation of fullness in the ear” in Japanese cluster headache patients. J Headache Pain 2014. [PMCID: PMC4181321 DOI: 10.1186/1129-2377-15-s1-c24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, Gupta V, Patsias A, Parides M, Demicco EG, Zhang DY, Kim-Schulze S, Kao J, Gnjatic S, Oh S, Posner MR, Sikora AG. Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res 2014; 74:7205-16. [PMID: 25320012 DOI: 10.1158/0008-5472.can-14-1913] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
While viral antigens in human papillomavirus (HPV)-related oropharyngeal cancer (HPVOPC) are attractive targets for immunotherapy, the effects of existing standard-of-care therapies on immune responses to HPV are poorly understood. We serially sampled blood from patients with stage III-IV oropharyngeal cancer undergoing concomitant chemoradiotherapy with or without induction chemotherapy. Circulating immunocytes including CD4(+) and CD8(+) T cells, regulatory T cells (Treg), and myeloid-derived suppressor cells (MDSC) were profiled by flow cytometry. Antigen-specific T-cell responses were measured in response to HPV16 E6 and E7 peptide pools. The role of PD-1 signaling in treatment-related immunosuppression was functionally defined by performing HPV-specific T-cell assays in the presence of blocking antibody. While HPV-specific T-cell responses were present in 13 of 18 patients before treatment, 10 of 13 patients lost these responses within 3 months after chemoradiotherapy. Chemoradiotherapy decreased circulating T cells and markedly elevated MDSCs. PD-1 expression on CD4(+) T cells increased by nearly 2.5-fold after chemoradiotherapy, and ex vivo culture with PD-1-blocking antibody enhanced HPV-specific T-cell responses in 8 of 18 samples tested. Chemoradiotherapy suppresses circulating immune responses in patients with HPVOPC by unfavorably altering effector:suppressor immunocyte ratios and upregulating PD-1 expression on CD4(+) T cells. These data strongly support testing of PD-1-blocking agents in combination with standard-of-care chemoradiotherapy for HPVOPC.
Collapse
Affiliation(s)
- Falguni Parikh
- Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York
| | | | - Naoko Imai
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Amelia Clark
- Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Krzys Misiukiewicz
- Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Marcello Bonomi
- Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Vishal Gupta
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alexis Patsias
- Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Michael Parides
- Health Evidence and Policy, Program, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Elizabeth G Demicco
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - David Y Zhang
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Seunghee Kim-Schulze
- Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Johnny Kao
- Department of Radiation Oncology, Good Samaritan Hospital Medical Center, West Islip, New York
| | - Sacha Gnjatic
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Sangkon Oh
- Baylor Institute of Immunology, Dallas, Texas
| | - Marshall R Posner
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Andrew G Sikora
- Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
| |
Collapse
|
42
|
Kageyama S, Ikeda H, Imai N, Ishihara M, Miyahara Y, Ueda S, Ishikawa T, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H. Abstract CT212: Adoptive transfer of wild-type TCR gene transduced T lymphocytes targeting MAGE-A4 antigen to patients with refractory esophageal cancer. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-ct212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:
Engineering an antigen receptor gene in patients' lymphocytes is one promising strategy to create antigen-specific lymphocytes without senescent phenotypes. The strategy provides an opportunity to extend the application of adoptive T cell therapy for cancer patients. However, this concept has not been tested in epithelial cancer patients.
Material and methods:
MAGE-A4-specific TCR α and β chains were isolated from a human T cell clone that recognizes MAGE-A4 143-151 peptide in an HLA-A*24:02 restricted manner. This T cell clone did not show any cross reactivity to the peptides with a homology to the MAGE-A4 epitope. A retroviral vector that encodes these TCR chains without any artificial modification was constructed; the lymphocytes transduced with the retroviral vector killed the MAGE-A4 expressing tumor in vitro and inhibited the tumor growth in the NOG immmunodeficient mice.
Patients were eligible if they had previously-treated recurrent MAGE-A4-expressing esophageal cancer, and were positive for HLA-A*24;02. Lymphocytes harvested from the patients were infected with the retroviral vector. The TCR-gene transduced T lymphocytes were once transferred to the patients without lymphocyte-depleting treatment, and MAGE-A4 peptide was given 2 and 4 weeks after. The cell doses were divided into 3 cohorts of 2x108 1x109 and 5x109, with a dose-escalating design, by evaluating the safety.
Results:
10 patients received the TCR-gene transduced T lymphocytes. No adverse events related to the cell transfer were observed. The TCR-gene transduced lymphocytes were detected in their peripheral blood in all 10 patients, which showed a dose-dependent appearance during the first 14 days, reaching peak and plateau levels from 3 to 7 days, and declined within 14 days. The cells persisted at 0.5% to 1% level in the peripheral mononuclear cells from day 14 to 63 after the cell transfer. In 6 patients whose blood samples had been collected for over 6 months, 3 patients maintained stable levels as long as 16 months, maintaining the immune reactivity to MAGE-A4-expressing tumor cells. In one patient, whose esophageal tumor was biopsied after the transfer, the TCR-gene transduced cells were detected in the tumor site.
7 patients developed tumor progressions within 2 months after the transfer. Their overall survivals were ranged from 3 to 18+ months, with a median of 10. 3 patients who had minimal tumor lesions at baseline have been free from disease-progression for 12, 15, and 19 months, respectively.
Conclusion:
Wild-type TCR-gene transduced lymphocytes targeting MAGE-A4 antigen were safely given to refractory esophageal cancer patients. The cells persisted in their peripheral blood in a dose-dependent manner in the early phase, and they have been stably persisting over 6 months. Three patients are free from disease progression more than a year. These results encourage us to proceed to further phase trials.
Citation Format: Shinichi Kageyama, Hiroaki Ikeda, Naoko Imai, Mikiya Ishihara, Yoshihiro Miyahara, Shugo Ueda, Takeshi Ishikawa, Hiroaki Naota, Kohshi Ohishi, Taizo Shiraishi, Naoki Inoue, Masashige Tanabe, Tomohide Kidokoro, Hirofumi Yoshioka, Daisuke Tomura, Ikuei Nukaya, Junichi Mineno, Kazutoh Takesako, Naoyuki Katayama, Hiroshi Shiku. Adoptive transfer of wild-type TCR gene transduced T lymphocytes targeting MAGE-A4 antigen to patients with refractory esophageal cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr CT212. doi:10.1158/1538-7445.AM2014-CT212
Collapse
Affiliation(s)
| | - Hiroaki Ikeda
- 1Mie University Graduate School of Medicine, Tsu, Japan
| | - Naoko Imai
- 1Mie University Graduate School of Medicine, Tsu, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Hiroshi Shiku
- 1Mie University Graduate School of Medicine, Tsu, Japan
| |
Collapse
|
43
|
Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y, Yamane M, Ueno H, Ideno M, Nukaya I, Enoki T, Mineno J, Takesako K, Hirano S, Shiku H. Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells. Eur J Immunol 2014; 44:1747-58. [PMID: 24723437 DOI: 10.1002/eji.201343969] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 02/11/2014] [Accepted: 04/04/2014] [Indexed: 01/01/2023]
Abstract
T cells express multiple integrin molecules. The significance of signaling through these molecules on acquisition of T-cell effector functions and memory formation capacity remains largely unknown. Moreover, the impact of stimulation through these signals on the generation of T cells for adoptive immunotherapy has not been elucidated. In this study, using a recombinant fragment of fibronectin, CH-296, we demonstrated that stimulation via very late Ag (VLA)-4 and VLA-5 in human and BALB/c mouse CD8(+) T cells, in combination with TCR stimulation, enhances effector multifunctionality and in vivo memory formation. Using TCR-transgenic mouse-derived CD8(+) T cells expressing TCR specific for the syngeneic CMS5 fibrosarcoma-derived tumor Ag, we showed that stimulation by CH-296 improved the ability of tumor-specific CD8(+) T cells to inhibit CMS5 tumor growth when adoptively transferred into hosts with progressing tumors. Improved antitumor effects were associated with decreased infiltration of Foxp3(+) CD4(+) Treg cells in tumors. These results suggest that stimulation via VLA-4 and VLA-5 modulates the qualities of effector T cells and could potentially increase the efficacy of adoptive therapy against cancer.
Collapse
Affiliation(s)
- Hayato Hosoi
- Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan; Department of Surgical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Kim YH, Watanabe YX, Hirayama Y, Imai N, Ishiyama H, Jeong SC, Miyatake H, Choi S, Song J, Clement E, de France G, Navin A, Rejmund M, Schmitt C, Pollarolo G, Corradi L, Fioretto E, Montanari D, Niikura M, Suzuki D, Nishibata H, Takatsu J. Study of the multi-nucleon transfer reactions of136Xe +198Pt for producing exotic heavy nuclei. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146603044] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Mukai M, Hirayama Y, Jeong SC, Imai N, Ishiyama H, Miyatake H, Oyaizu M, Watanabe YX, Kim YH. In-gas-cell laser ion source for KEK isotope separation system. Rev Sci Instrum 2014; 85:02B906. [PMID: 24593611 DOI: 10.1063/1.4827112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The KEK isotope separation system (KISS) is an element-selective isotope separator under development at RIKEN. The in-gas-cell laser ion source is a critical component of the KISS, a gas cell filled with argon gas of 50 kPa enclosed in a vacuum chamber. In the gas cell, nuclear reaction products are stopped (i.e., thermalized and neutralized) and transported by a laminar flow of argon to the ionization region just upstream of the gas outlet, and thereby an element of interest among those reaction products is selectively ionized by two-color resonant laser irradiation. Recently, we succeeded to extract laser-ionized Fe ions by injecting an energetic Fe beam into the gas cell. Recent off- and on-line test results were presented and discussed.
Collapse
Affiliation(s)
- M Mukai
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - Y Hirayama
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - S C Jeong
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - N Imai
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - H Ishiyama
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - H Miyatake
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - M Oyaizu
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - Y X Watanabe
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| | - Y H Kim
- High Energy Accelerator Res Org. (KEK), Ibaraki 305-0801, Japan
| |
Collapse
|
46
|
Hirayama Y, Jeong S, Watanabe Y, Imai N, Ishiyama H, Miyatake H, Oyaizu M, Kim Y, Mukai M, Sonoda T, Wada M, Huyse M, Kudryavtsev Y, Van Duppen P. Present Status of KEK Isotope Separation System. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146611017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
|
48
|
Ikeda H, Kageyama S, Imai N, Miyahara Y, Ishihara M, Katayama N, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Shiku H. In vivo persistence of adoptively transferred TCR gene-transduced lymphocytes with anti-tumor reactivity in patients with MAGE-A4 expressing esophageal cancer. J Immunother Cancer 2013. [PMCID: PMC3991198 DOI: 10.1186/2051-1426-1-s1-o3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
49
|
Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med 2013; 11:246. [PMID: 24093426 PMCID: PMC4015172 DOI: 10.1186/1479-5876-11-246] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2013] [Accepted: 09/30/2013] [Indexed: 11/10/2022] Open
Abstract
Background Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received the CHP-NY-ESO-1 complex vaccine, Drug code: IMF-001. Methods Patients with advanced/metastatic esophageal cancer were enrolled and subcutaneously vaccinated with either 100 μg or 200 μg of NY-ESO-1 protein complexed with CHP. The primary endpoints were safety and humoral immune responses, and the secondary endpoint was clinical efficacy. Results A total of 25 patients were enrolled. Thirteen and twelve patients were repeatedly vaccinated with 100 μg or 200 μg of CHP-NY-ESO-1 with a median of 8 or 9.5 doses, respectively. No serious adverse events related to the vaccine were observed. Three out of 13 patients in the 100-μg cohort and 7 out of 12 patients in the 200-μg cohort were positive for anti-NY-ESO-1 antibodies at baseline. In the 100-μg cohort, an antibody response was observed in 5 out of 10 pre-antibody-negatives patients, and the antibody levels were augmented in 2 pre-antibody-positive patients after vaccination. In the 200-μg cohort, all 5 pre-antibody-negative patients became seropositive, and the antibody level was amplified in all 7 pre-antibody-positive patients. No tumor shrinkage was observed. The patients who received 200 μg of CHP-NY-ESO-1 survived longer than patients receiving 100 μg of CHP-NY-ESO-1, even those who exhibited unresponsiveness to previous therapies or had higher tumor burdens. Conclusions The safety and immunogenicity of CHP-NY-ESO-1 vaccine were confirmed. The 200 μg dose more efficiently induced immune responses and suggested better survival benefits. (Clinical trial registration number NCT01003808).
Collapse
Affiliation(s)
- Shinichi Kageyama
- Departments of Immuno-Gene Therapy and Cancer Vaccine, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie 514-8507, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
|